<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:52:52 -0700</creation_date>
  <update_date>2013-05-27 11:08:35 -0600</update_date>
  <accession>HMDBP01018</accession>
  <secondary_accessions>
    <accession>6306</accession>
    <accession>HMDBP07095</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>Albendazole monooxygenase</synonym>
    <synonym>Albendazole sulfoxidase</synonym>
    <synonym>CYPIIIA3</synonym>
    <synonym>CYPIIIA4</synonym>
    <synonym>Cytochrome P450 3A3</synonym>
    <synonym>Cytochrome P450 HLp</synonym>
    <synonym>Cytochrome P450 NF-25</synonym>
    <synonym>Cytochrome P450-PCN1</synonym>
    <synonym>Nifedipine oxidase</synonym>
    <synonym>Quinine 3-monooxygenase</synonym>
    <synonym>Taurochenodeoxycholate 6-alpha-hydroxylase</synonym>
    <synonym>1,8-cineole 2-exo-monooxygenase</synonym>
  </synonyms>
  <gene_name>CYP3A4</gene_name>
  <general_function>Involved in monooxygenase activity</general_function>
  <specific_function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide.
</specific_function>
  <pathways>
    <pathway>
      <name>Steroid hormone biosynthesis</name>
      <smpdb_id/>
      <kegg_map_id>map00140</kegg_map_id>
    </pathway>
    <pathway>
      <name>Linoleic acid metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00591</kegg_map_id>
    </pathway>
    <pathway>
      <name>Retinol metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00830</kegg_map_id>
    </pathway>
    <pathway>
      <name>Metabolism of xenobiotics by cytochrome P450</name>
      <smpdb_id/>
      <kegg_map_id>map00980</kegg_map_id>
    </pathway>
    <pathway>
      <name>Drug metabolism - cytochrome P450</name>
      <smpdb_id/>
      <kegg_map_id>map00982</kegg_map_id>
    </pathway>
    <pathway>
      <name>Drug metabolism - other enzymes</name>
      <smpdb_id/>
      <kegg_map_id>map00983</kegg_map_id>
    </pathway>
    <pathway>
      <name>Bile secretion</name>
      <smpdb_id/>
      <kegg_map_id>map04976</kegg_map_id>
    </pathway>
    <pathway>
      <name>Chemical carcinogenesis</name>
      <smpdb_id/>
      <kegg_map_id>map05204</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB03178</accession>
      <name>Heme</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00217</accession>
      <name>NADP</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00221</accession>
      <name>NADPH</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01984</accession>
      <name>Finasteride</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05018</accession>
      <name>Amlodipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01913</accession>
      <name>Omeprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05006</accession>
      <name>Atorvastatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05028</accession>
      <name>Escitalopram</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01939</accession>
      <name>Medroxyprogesterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05033</accession>
      <name>Valdecoxib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05007</accession>
      <name>Simvastatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05000</accession>
      <name>Loratadine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05021</accession>
      <name>Quetiapine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05035</accession>
      <name>Ondansetron</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00234</accession>
      <name>Testosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05030</accession>
      <name>Fexofenadine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05026</accession>
      <name>Rabeprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01927</accession>
      <name>Diphenhydramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05042</accession>
      <name>Aripiprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05017</accession>
      <name>Pantoprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05023</accession>
      <name>Zolpidem</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01944</accession>
      <name>Chlorpheniramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04999</accession>
      <name>Loperamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05041</accession>
      <name>Donepezil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05011</accession>
      <name>Clopidogrel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00053</accession>
      <name>Androstenedione</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00142</accession>
      <name>Formic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00145</accession>
      <name>Estrone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00151</accession>
      <name>Estradiol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00673</accession>
      <name>Linoleic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01043</accession>
      <name>Arachidonic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01355</accession>
      <name>Parathion</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01377</accession>
      <name>Oxygen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01426</accession>
      <name>Formaldehyde</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01847</accession>
      <name>Caffeine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01852</accession>
      <name>All-trans-retinoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01860</accession>
      <name>Paraxanthine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01877</accession>
      <name>Valproic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02111</accession>
      <name>Water</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02190</accession>
      <name>5,6-Epoxy-8,11,14-eicosatrienoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02232</accession>
      <name>8,9-Epoxyeicosatrienoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02833</accession>
      <name>Testosterone sulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03276</accession>
      <name>Hydrogen sulfide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03955</accession>
      <name>19-Hydroxyandrost-4-ene-3,17-dione</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03956</accession>
      <name>7a-Hydroxytestosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03959</accession>
      <name>19-Oxotestosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04081</accession>
      <name>6-Hydroxymelatonin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04244</accession>
      <name>15(S)-HPETE</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04264</accession>
      <name>14,15-Epoxy-5,8,11-eicosatrienoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04673</accession>
      <name>11,12-Epoxyeicosatrienoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04680</accession>
      <name>16(R)-HETE</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04684</accession>
      <name>11,12,15-THETA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04693</accession>
      <name>11H-14,15-EETA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04694</accession>
      <name>11,14,15-THETA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04701</accession>
      <name>9,10-Epoxyoctadecenoic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04702</accession>
      <name>12,13-EpOME</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04995</accession>
      <name>Codeine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05038</accession>
      <name>Citalopram</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05050</accession>
      <name>15H-11,12-EETA</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06768</accession>
      <name>19-Oxoandrost-4-ene-3,17-dione</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06769</accession>
      <name>19-Hydroxytestosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11136</accession>
      <name>19(S)-HETE</name>
    </metabolite>
    <metabolite>
      <accession>HMDB11637</accession>
      <name>Taurohyocholate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01091</accession>
      <name>3-Hydroxyquinine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12242</accession>
      <name>Ketoconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12567</accession>
      <name>13-HETE</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12598</accession>
      <name>17-HETE</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00900</accession>
      <name>Ergocalciferol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00876</accession>
      <name>Vitamin D3</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14322</accession>
      <name>Fluvoxamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14326</accession>
      <name>Flunisolide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01934</accession>
      <name>L(-)-Nicotine pestanal</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14331</accession>
      <name>Cevimeline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14334</accession>
      <name>Bortezomib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14339</accession>
      <name>Tramadol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14342</accession>
      <name>Fluconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14344</accession>
      <name>Erythromycin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14349</accession>
      <name>Dofetilide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14352</accession>
      <name>Azithromycin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13921</accession>
      <name>7-Hydroxyticlopidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14021</accession>
      <name>N-Desmethylcitalopram</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13919</accession>
      <name>N-Desmethyleletriptan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14365</accession>
      <name>Nelfinavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14369</accession>
      <name>Indinavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14372</accession>
      <name>Lovastatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14376</accession>
      <name>Temazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14379</accession>
      <name>Reboxetine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13911</accession>
      <name>12-Hydroxynevirapine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14384</accession>
      <name>Oxiconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14385</accession>
      <name>Alclometasone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14388</accession>
      <name>Ranolazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14391</accession>
      <name>Ziprasidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14393</accession>
      <name>Cabergoline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13851</accession>
      <name>N-Acetyldapsone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13895</accession>
      <name>3',4'-Dihydrodiol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14399</accession>
      <name>Doxycycline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14400</accession>
      <name>Diethylstilbestrol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14404</accession>
      <name>Sulfanilamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14413</accession>
      <name>Ropinirole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14415</accession>
      <name>Isradipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01889</accession>
      <name>Theophylline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14423</accession>
      <name>Argatroban</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14425</accession>
      <name>Disopyramide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14426</accession>
      <name>Lidocaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14428</accession>
      <name>Clemastine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14434</accession>
      <name>Atomoxetine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14439</accession>
      <name>Etonogestrel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14440</accession>
      <name>Morphine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14441</accession>
      <name>Ropivacaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14442</accession>
      <name>Bupivacaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14446</accession>
      <name>Flucloxacillin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14452</accession>
      <name>Bexarotene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14454</accession>
      <name>Vindesine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14457</accession>
      <name>Pentobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13897</accession>
      <name>4-ene-Valproic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14462</accession>
      <name>Gefitinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14465</accession>
      <name>Dihydroergotamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14469</accession>
      <name>Fluorometholone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14476</accession>
      <name>Ipratropium bromide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14477</accession>
      <name>Methadone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14481</accession>
      <name>Pimecrolimus</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14010</accession>
      <name>5-Hydroxyomeprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14483</accession>
      <name>Pyrazinamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14486</accession>
      <name>Terfenadine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14487</accession>
      <name>Diltiazem</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14490</accession>
      <name>Alfuzosin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14491</accession>
      <name>Trimethadione</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14493</accession>
      <name>Clobazam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14497</accession>
      <name>Methylergonovine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14500</accession>
      <name>Chlorzoxazone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14501</accession>
      <name>Aminoglutethimide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14502</accession>
      <name>Mefloquine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14503</accession>
      <name>Sulfadiazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14505</accession>
      <name>Vinorelbine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14509</accession>
      <name>Grepafloxacin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14511</accession>
      <name>Levonorgestrel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14514</accession>
      <name>Mirtazapine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14521</accession>
      <name>Palonosetron</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14523</accession>
      <name>Mexiletine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14534</accession>
      <name>Digoxin n</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14537</accession>
      <name>Nimodipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01830</accession>
      <name>Progesterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14542</accession>
      <name>Sorafenib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14544</accession>
      <name>Griseofulvin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14545</accession>
      <name>Nisoldipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13943</accession>
      <name>Alpha-hydroxyalprazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13938</accession>
      <name>Promazine 5-sulfoxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14570</accession>
      <name>Famciclovir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14577</accession>
      <name>Prochlorperazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14583</accession>
      <name>Trimethoprim</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14586</accession>
      <name>Betamethasone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14587</accession>
      <name>Teniposide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14589</accession>
      <name>Chloramphenicol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14008</accession>
      <name>Hydroxylansoprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14597</accession>
      <name>Meperidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14611</accession>
      <name>Quinine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14613</accession>
      <name>Dronabinol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14614</accession>
      <name>Montelukast</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14618</accession>
      <name>Chlordiazepoxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14620</accession>
      <name>Chlorpromazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14624</accession>
      <name>Raloxifene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13995</accession>
      <name>Hydroxycelecoxib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14628</accession>
      <name>Dicloxacillin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14633</accession>
      <name>Buspirone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14638</accession>
      <name>Zidovudine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14639</accession>
      <name>Darifenacin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14640</accession>
      <name>Oxycodone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14642</accession>
      <name>Flutamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14644</accession>
      <name>Cimetidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14645</accession>
      <name>Haloperidol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14646</accession>
      <name>Ritonavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14659</accession>
      <name>Albendazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14661</accession>
      <name>Caspofungin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14669</accession>
      <name>Lercanidipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14671</accession>
      <name>Erlotinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13856</accession>
      <name>4-Hydroxycyclophosphamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14677</accession>
      <name>Ciprofloxacin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14679</accession>
      <name>Toremifene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14680</accession>
      <name>Nortriptyline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14681</accession>
      <name>Vincristine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14685</accession>
      <name>Pyridostigmine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14686</accession>
      <name>Adinazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14689</accession>
      <name>Zafirlukast</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14693</accession>
      <name>Methoxsalen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14699</accession>
      <name>Bosentan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14704</accession>
      <name>Carbamazepine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14707</accession>
      <name>Cephalexin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14710</accession>
      <name>Vinblastine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14720</accession>
      <name>Voriconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14722</accession>
      <name>Enalapril</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13974</accession>
      <name>4'-Hydroxydiclofenac</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14726</accession>
      <name>Fluticasone Propionate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14727</accession>
      <name>Lisuride</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14731</accession>
      <name>Ethosuximide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14737</accession>
      <name>Thiopental</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14740</accession>
      <name>Ivermectin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14742</accession>
      <name>Cisapride</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14745</accession>
      <name>Nafcillin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14746</accession>
      <name>Chloroquine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14750</accession>
      <name>Bisoprolol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14753</accession>
      <name>Rifabutin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14755</accession>
      <name>Paramethadione</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13862</accession>
      <name>N-desmethylimatinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14760</accession>
      <name>Nicardipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14763</accession>
      <name>Efavirenz</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14766</accession>
      <name>Clorazepate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14773</accession>
      <name>Prednisone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14774</accession>
      <name>Clofibrate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14775</accession>
      <name>Astemizole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14781</accession>
      <name>Mebendazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14785</accession>
      <name>Propoxyphene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14794</accession>
      <name>Trazodone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13961</accession>
      <name>O-Desmethylverapamil (D-702)</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14805</accession>
      <name>Histamine Phosphate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14811</accession>
      <name>Aprepitant</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14812</accession>
      <name>Galantamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13866</accession>
      <name>N-Desmethyltamoxifen</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13846</accession>
      <name>E-3179</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13880</accession>
      <name>S-6-Hydroxywarfarin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14821</accession>
      <name>Midazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14828</accession>
      <name>Flurazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14832</accession>
      <name>Daunorubicin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14834</accession>
      <name>Ergotamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14838</accession>
      <name>Eplerenone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14839</accession>
      <name>Amprenavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14841</accession>
      <name>Methazolamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14843</accession>
      <name>Delavirdine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14844</accession>
      <name>Tamsulosin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14846</accession>
      <name>Sufentanil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14855</accession>
      <name>Norethindrone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14857</accession>
      <name>Azatadine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14862</accession>
      <name>Imiquimod</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14864</accession>
      <name>Trimipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14869</accession>
      <name>Nateglinide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14874</accession>
      <name>Esomeprazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14876</accession>
      <name>Pentamidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14879</accession>
      <name>Hydrocortisone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13968</accession>
      <name>Hydroxyzileuton</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14883</accession>
      <name>Modafinil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14886</accession>
      <name>Carbinoxamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14889</accession>
      <name>Epinastine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14890</accession>
      <name>Tranylcypromine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14895</accession>
      <name>Dolasetron</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13929</accession>
      <name>2-Oxoclopidogrel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14897</accession>
      <name>Tetracycline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14900</accession>
      <name>Irinotecan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14901</accession>
      <name>Methimazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14906</accession>
      <name>Olopatadine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14907</accession>
      <name>Hydrocortamate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14911</accession>
      <name>Etoposide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14914</accession>
      <name>Oxcarbazepine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14916</accession>
      <name>Roxithromycin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14918</accession>
      <name>Phenelzine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14932</accession>
      <name>Primidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14940</accession>
      <name>Alfentanil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14946</accession>
      <name>Indapamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14950</accession>
      <name>Phenylbutazone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14951</accession>
      <name>Fentanyl</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14952</accession>
      <name>Meloxicam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14018</accession>
      <name>4-Hydroxypropofol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14957</accession>
      <name>Acetazolamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14958</accession>
      <name>Tadalafil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14960</accession>
      <name>Disulfiram</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14972</accession>
      <name>Mifepristone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14980</accession>
      <name>Oxazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13958</accession>
      <name>5-O-Desmethyldonepezil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14983</accession>
      <name>Clofazimine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14988</accession>
      <name>Perphenazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14991</accession>
      <name>Temozolomide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14994</accession>
      <name>Chlorphenesin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14995</accession>
      <name>Terbinafine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14998</accession>
      <name>Prednisolone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15000</accession>
      <name>Vardenafil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15002</accession>
      <name>Tacrolimus</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15003</accession>
      <name>Benzphetamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15007</accession>
      <name>Dorzolamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15010</accession>
      <name>Conivaptan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15015</accession>
      <name>Sirolimus</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15020</accession>
      <name>Clomifene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15021</accession>
      <name>Isosorbide Dinitrate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15026</accession>
      <name>Granisetron</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15034</accession>
      <name>Triazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00108</accession>
      <name>Ethanol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15042</accession>
      <name>Tiagabine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15043</accession>
      <name>Cocaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15044</accession>
      <name>Quinidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15045</accession>
      <name>Zonisamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15046</accession>
      <name>Paricalcitol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15047</accession>
      <name>Tinidazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15048</accession>
      <name>Repaglinide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15052</accession>
      <name>Metronidazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15054</accession>
      <name>Almotriptan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15060</accession>
      <name>Cyclobenzaprine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15061</accession>
      <name>Phenoxybenzamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15067</accession>
      <name>Tipranavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15073</accession>
      <name>Salmeterol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15078</accession>
      <name>Zalcitabine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15081</accession>
      <name>Phenprocoumon</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15082</accession>
      <name>Fulvestrant</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15084</accession>
      <name>Felbamate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15086</accession>
      <name>Isoniazid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15091</accession>
      <name>Hydrocodone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15094</accession>
      <name>Methylprednisolone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15097</accession>
      <name>Zaleplon</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15104</accession>
      <name>Alosetron</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15108</accession>
      <name>Ezetimibe</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15111</accession>
      <name>Telithromycin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01926</accession>
      <name>17a-Ethynylestradiol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15115</accession>
      <name>Ramelteon</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15122</accession>
      <name>Cytarabine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15124</accession>
      <name>Rivastigmine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15125</accession>
      <name>Exemestane</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15132</accession>
      <name>Doxorubicin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15137</accession>
      <name>Levobupivacaine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15141</accession>
      <name>Letrozole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15142</accession>
      <name>Tioconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15143</accession>
      <name>Busulfan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15146</accession>
      <name>Metyrapone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15147</accession>
      <name>Cinacalcet</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15151</accession>
      <name>Glyburide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15153</accession>
      <name>Guanfacine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15155</accession>
      <name>Isosorbide Mononitrate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15158</accession>
      <name>Felodipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15162</accession>
      <name>Methoxyflurane</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13845</accession>
      <name>SR 49498</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15164</accession>
      <name>Topotecan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15166</accession>
      <name>Probenecid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13972</accession>
      <name>N-Dealkylated tolterodine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15171</accession>
      <name>Selegiline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15173</accession>
      <name>Fenofibrate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15179</accession>
      <name>Rifampin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15183</accession>
      <name>Ergoloid mesylate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15187</accession>
      <name>Nitrendipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15191</accession>
      <name>Praziquantel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15192</accession>
      <name>Norfloxacin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15195</accession>
      <name>Oxybutynin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15200</accession>
      <name>Glipizide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15201</accession>
      <name>Clonazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15204</accession>
      <name>Mequitazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15205</accession>
      <name>Atazanavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15207</accession>
      <name>Perhexiline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15215</accession>
      <name>Orlistat</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15217</accession>
      <name>Pilocarpine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15219</accession>
      <name>Primaquine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02151</accession>
      <name>Dimethyl sulfoxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14037</accession>
      <name>6-Hydroxyfluvastatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15230</accession>
      <name>Rosuvastatin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15232</accession>
      <name>Pimozide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15235</accession>
      <name>Quinacrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15237</accession>
      <name>Sibutramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15242</accession>
      <name>Miconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15247</accession>
      <name>Nifedipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15258</accession>
      <name>Dutasteride</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15259</accession>
      <name>Econazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15260</accession>
      <name>Bicalutamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15263</accession>
      <name>Proguanil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15264</accession>
      <name>Pioglitazone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13946</accession>
      <name>8-Hydroxycarvedilol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15269</accession>
      <name>Sulfinpyrazone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15280</accession>
      <name>Nefazodone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15282</accession>
      <name>Desipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14118</accession>
      <name>Trifluoroacetic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15297</accession>
      <name>Cilostazol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15298</accession>
      <name>Itraconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15300</accession>
      <name>Arsenic trioxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15301</accession>
      <name>Guanethidine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15304</accession>
      <name>Orphenadrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15310</accession>
      <name>Podofilox</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13858</accession>
      <name>3-Dechloroethylifosfamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15313</accession>
      <name>Propafenone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15314</accession>
      <name>Naloxone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15315</accession>
      <name>Domperidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15317</accession>
      <name>Pergolide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15321</accession>
      <name>Clindamycin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15323</accession>
      <name>Oxymorphone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15325</accession>
      <name>Brinzolamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15327</accession>
      <name>Estramustine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15329</accession>
      <name>Zopiclone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15331</accession>
      <name>Bromocriptine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15332</accession>
      <name>Rifapentine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15335</accession>
      <name>Mitoxantrone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15337</accession>
      <name>Lomustine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15342</accession>
      <name>Clarithromycin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15346</accession>
      <name>Estazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15347</accession>
      <name>Finasteride  e</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15348</accession>
      <name>Anastrozole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15349</accession>
      <name>Halofantrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15350</accession>
      <name>Dantrolene</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15351</accession>
      <name>Rifaximin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15353</accession>
      <name>Budesonide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15354</accession>
      <name>Aminophylline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15358</accession>
      <name>Levomethadyl Acetate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15360</accession>
      <name>Paclitaxel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15362</accession>
      <name>Saquinavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15364</accession>
      <name>Dexamethasone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15366</accession>
      <name>Sevoflurane</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15371</accession>
      <name>Gemfibrozil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15372</accession>
      <name>Clomipramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15376</accession>
      <name>Trimeprazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15378</accession>
      <name>Docetaxel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15383</accession>
      <name>Ergonovine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15384</accession>
      <name>Dasatinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15386</accession>
      <name>Retapamulin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15387</accession>
      <name>Aliskiren</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15388</accession>
      <name>Lapatinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15390</accession>
      <name>Sitagliptin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15392</accession>
      <name>Posaconazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15393</accession>
      <name>Darunavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15396</accession>
      <name>Paliperidone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15397</accession>
      <name>Sunitinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15400</accession>
      <name>Hydralazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15414</accession>
      <name>Rolitetracycline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15416</accession>
      <name>Fosamprenavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15417</accession>
      <name>Fosphenytoin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15418</accession>
      <name>Josamycin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15428</accession>
      <name>Cefradine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15439</accession>
      <name>Tasosartan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13940</accession>
      <name>3'-Hydroxyhexobarbital</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15448</accession>
      <name>Troleandomycin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15455</accession>
      <name>Quinupristin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15459</accession>
      <name>Cortisone acetate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15462</accession>
      <name>Paramethasone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15464</accession>
      <name>Yohimbine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15465</accession>
      <name>Bezafibrate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15466</accession>
      <name>Colchicine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15468</accession>
      <name>Digitoxin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15479</accession>
      <name>Tiotropium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15480</accession>
      <name>Ciclesonide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15481</accession>
      <name>Pranlukast</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15487</accession>
      <name>Acenocoumarol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13839</accession>
      <name>N-Desmethylaminopyrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15500</accession>
      <name>Allylestrenol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13840</accession>
      <name>3-Hydroxymethylantipyrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15509</accession>
      <name>Ethylmorphine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15510</accession>
      <name>Flunitrazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15511</accession>
      <name>Bromazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15512</accession>
      <name>Clotiazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15526</accession>
      <name>Ketazolam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15527</accession>
      <name>Prazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15528</accession>
      <name>Quazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15529</accession>
      <name>Everolimus</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15530</accession>
      <name>Solifenacin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15534</accession>
      <name>Nitrazepam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15539</accession>
      <name>Lopinavir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15547</accession>
      <name>Deferasirox</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15558</accession>
      <name>Pipotiazine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB13997</accession>
      <name>6-Hydroxymethyletoricoxib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03249</accession>
      <name>Rutin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15566</accession>
      <name>Dalfopristin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01406</accession>
      <name>Niacinamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15576</accession>
      <name>Thiotepa</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15583</accession>
      <name>Bifonazole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB38854</accession>
      <name>3-O-beta-D-Galactopyranosyl-L-arabinose</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15584</accession>
      <name>Maraviroc</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15593</accession>
      <name>Ixabepilone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15595</accession>
      <name>Nilotinib</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15604</accession>
      <name>Permethrin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15608</accession>
      <name>Indacaterol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15609</accession>
      <name>Trabectedin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15615</accession>
      <name>Rotigotine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15616</accession>
      <name>Telaprevir</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15618</accession>
      <name>Sertindole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15620</accession>
      <name>Mianserin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15623</accession>
      <name>Rimonabant</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15628</accession>
      <name>Udenafil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15629</accession>
      <name>Sitaxentan</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15632</accession>
      <name>Temsirolimus</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15634</accession>
      <name>Saxagliptin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15637</accession>
      <name>Vilazodone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15643</accession>
      <name>Artemether</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15646</accession>
      <name>Desvenlafaxine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15648</accession>
      <name>Fesoterodine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15653</accession>
      <name>Lumefantrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15655</accession>
      <name>Methyltestosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15657</accession>
      <name>Nilvadipine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15661</accession>
      <name>Fospropofol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15662</accession>
      <name>Fosaprepitant</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15672</accession>
      <name>Cabazitaxel</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15699</accession>
      <name>Tofisopam</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15702</accession>
      <name>Ticagrelor</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15705</accession>
      <name>Ivacaftor</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00951</accession>
      <name>Taurochenodesoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00761</accession>
      <name>Lithocholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00733</accession>
      <name>Hyodeoxycholic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB59609</accession>
      <name>albendazole S-oxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04472</accession>
      <name>Eucalyptol</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>heme binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>electron carrier activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cation binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transition metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>iron ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>monooxygenase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>oxidation reduction</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>cell surface</description>
      <go_id>GO:0009986</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>endoplasmic reticulum membrane</description>
      <go_id>GO:0005789</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>integral to membrane</description>
      <go_id>GO:0016021</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>albendazole monooxygenase activity</description>
      <go_id>GO:0047638</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>caffeine oxidase activity</description>
      <go_id>GO:0034875</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>electron carrier activity</description>
      <go_id>GO:0009055</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>heme binding</description>
      <go_id>GO:0020037</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>iron ion binding</description>
      <go_id>GO:0005506</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
      <go_id>GO:0016712</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>oxygen binding</description>
      <go_id>GO:0019825</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>quinine 3-monooxygenase activity</description>
      <go_id>GO:0050591</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>steroid binding</description>
      <go_id>GO:0005496</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>taurochenodeoxycholate 6alpha-hydroxylase activity</description>
      <go_id>GO:0033780</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>testosterone 6-beta-hydroxylase activity</description>
      <go_id>GO:0050649</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>vitamin D 24-hydroxylase activity</description>
      <go_id>GO:0070576</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>vitamin D3 25-hydroxylase activity</description>
      <go_id>GO:0030343</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>alkaloid catabolic process</description>
      <go_id>GO:0009822</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>androgen metabolic process</description>
      <go_id>GO:0008209</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>exogenous drug catabolic process</description>
      <go_id>GO:0042738</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>heterocycle metabolic process</description>
      <go_id>GO:0046483</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>monoterpenoid metabolic process</description>
      <go_id>GO:0016098</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>oxidative demethylation</description>
      <go_id>GO:0070989</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>steroid catabolic process</description>
      <go_id>GO:0006706</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>vitamin D metabolic process</description>
      <go_id>GO:0042359</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>xenobiotic metabolic process</description>
      <go_id>GO:0006805</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Endoplasmic reticulum membrane</subcellular_location>
    <subcellular_location>Single-pass membrane protein</subcellular_location>
    <subcellular_location>Microsome membrane</subcellular_location>
    <subcellular_location>Single-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>7</chromosome_location>
    <locus>7q21.1</locus>
    <gene_sequence>&gt;1512 bp
ATGGCTCTCATCCCAGACTTGGCCATGGAAACCCGGCTTCTCCTGGCTGTCAGCCTGGTG
CTCCTCTATCTATATGGAACTCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG
CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT
GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT
GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT
GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA
GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA
AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG
AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC
ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA
GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT
CTCTCAATAACAGTCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTG
TTTCCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGC
CTCGAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAAT
TCAAAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATT
ATCTTTATTTTTGCTGGCTGTGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAA
CTGGCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCC
AATAAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTG
AATGAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGAT
GTTGAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCT
CTTCACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGC
AAGAAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGA
AACTGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTT
CAGAACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGA
GGACTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTA
AGTGGAGCCTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>503</residue_number>
    <molecular_weight>57255.585</molecular_weight>
    <theoretical_pi>8.097</theoretical_pi>
    <pfams>
      <pfam>
        <name>p450</name>
        <pfam_id>PF00067</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA</protein_sequence>
  </protein_properties>
  <genbank_protein_id>6470135</genbank_protein_id>
  <uniprot_id>P08684</uniprot_id>
  <uniprot_name>CP3A4_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1TQN</pdb_id>
    <pdb_id>1W0E</pdb_id>
    <pdb_id>1W0F</pdb_id>
    <pdb_id>1W0G</pdb_id>
    <pdb_id>2J0D</pdb_id>
    <pdb_id>2V0M</pdb_id>
    <pdb_id>3NXU</pdb_id>
    <pdb_id>3TJS</pdb_id>
    <pdb_id>3UA1</pdb_id>
  </pdb_ids>
  <genbank_gene_id>AF182273</genbank_gene_id>
  <genecard_id>CYP3A4</genecard_id>
  <geneatlas_id>CYP3A4</geneatlas_id>
  <hgnc_id>HGNC:2637</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Molowa DT, Schuetz EG, Wrighton SA, Watkins PB, Kremers P, Mendez-Picon G, Parker GA, Guzelian PS: Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver. Proc Natl Acad Sci U S A. 1986 Jul;83(14):5311-5.</reference_text>
      <pubmed_id>3460094</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gonzalez FJ, Schmid BJ, Umeno M, Mcbride OW, Hardwick JP, Meyer UA, Gelboin HV, Idle JR: Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA. 1988 Mar;7(2):79-86.</reference_text>
      <pubmed_id>3267210</pubmed_id>
    </reference>
    <reference>
      <reference_text>Beaune PH, Umbenhauer DR, Bork RW, Lloyd RS, Guengerich FP: Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8064-8.</reference_text>
      <pubmed_id>3464943</pubmed_id>
    </reference>
    <reference>
      <reference_text>Spurr NK, Gough AC, Stevenson K, Wolf CR: The human cytochrome P450 CYP3 locus: assignment to chromosome 7q22-qter.  Hum Genet. 1989 Jan;81(2):171-4.</reference_text>
      <pubmed_id>2563251</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bork RW, Muto T, Beaune PH, Srivastava PK, Lloyd RS, Guengerich FP: Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. J Biol Chem. 1989 Jan 15;264(2):910-9.</reference_text>
      <pubmed_id>2463251</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chen Q, Wu J, Yu Y: [Establishment of transgenic cell line CHL-3A4 and its metabolic activation] Zhonghua Yu Fang Yi Xue Za Zhi. 1998 Sep;32(5):281-4.</reference_text>
      <pubmed_id>10322772</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, Deglmann CJ, Burk O, Buntefuss D, Escher S, Bishop C, Koebe HG, Brinkmann U, Klenk HP, Kleine K, Meyer UA, Wojnowski L: Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics. 2001 Mar;11(2):111-21.</reference_text>
      <pubmed_id>11266076</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hsieh KP, Lin YY, Cheng CL, Lai ML, Lin MS, Siest JP, Huang JD: Novel mutations of CYP3A4 in Chinese.  Drug Metab Dispos. 2001 Mar;29(3):268-73.</reference_text>
      <pubmed_id>11181494</pubmed_id>
    </reference>
    <reference>
      <reference_text>Komori M, Hashizume T, Ohi H, Miura T, Kitada M, Nagashima K, Kamataki T: Cytochrome P-450 in human liver microsomes: high-performance liquid chromatographic isolation of three forms and their characterization. J Biochem. 1988 Dec;104(6):912-6.</reference_text>
      <pubmed_id>3243766</pubmed_id>
    </reference>
    <reference>
      <reference_text>Watkins PB, Wrighton SA, Maurel P, Schuetz EG, Mendez-Picon G, Parker GA, Guzelian PS: Identification of an inducible form of cytochrome P-450 in human liver.  Proc Natl Acad Sci U S A. 1985 Sep;82(18):6310-4.</reference_text>
      <pubmed_id>3898085</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S: Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.  Br J Clin Pharmacol. 1997 Mar;43(3):245-52.</reference_text>
      <pubmed_id>9088578</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zhao XJ, Kawashiro T, Ishizaki T: Mutual inhibition between quinine and etoposide by human liver microsomes. Evidence for cytochrome P4503A4 involvement in their major metabolic pathways. Drug Metab Dispos. 1998 Feb;26(2):188-91.</reference_text>
      <pubmed_id>9456308</pubmed_id>
    </reference>
    <reference>
      <reference_text>Pabarcus MK, Hoe N, Sadeghi S, Patterson C, Wiertz E, Correia MA: CYP3A4 ubiquitination by gp78 (the tumor autocrine motility factor receptor, AMFR) and CHIP E3 ligases. Arch Biochem Biophys. 2009 Mar 1;483(1):66-74. Epub 2008 Dec 10.</reference_text>
      <pubmed_id>19103148</pubmed_id>
    </reference>
    <reference>
      <reference_text>Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF: The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol Chem. 2004 Sep 10;279(37):38091-4. Epub 2004 Jul 16.</reference_text>
      <pubmed_id>15258162</pubmed_id>
    </reference>
    <reference>
      <reference_text>Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, Jhoti H: Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science. 2004 Jul 30;305(5684):683-6. Epub 2004 Jul 15.</reference_text>
      <pubmed_id>15256616</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, Gonzalez FJ: CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther. 2000 Jan;67(1):48-56.</reference_text>
      <pubmed_id>10668853</pubmed_id>
    </reference>
    <reference>
      <reference_text>Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, Goldstein JA: Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther. 2001 Dec;299(3):825-31.</reference_text>
      <pubmed_id>11714865</pubmed_id>
    </reference>
    <reference>
      <reference_text>Eiselt R, Domanski TL, Zibat A, Mueller R, Presecan-Siedel E, Hustert E, Zanger UM, Brockmoller J, Klenk HP, Meyer UA, Khan KK, He YA, Halpert JR, Wojnowski L: Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics. 2001 Jul;11(5):447-58.</reference_text>
      <pubmed_id>11470997</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, Schuetz EG: Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics. 2002 Mar;12(2):121-32.</reference_text>
      <pubmed_id>11875366</pubmed_id>
    </reference>
    <reference>
      <reference_text>Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL, Dawson EP: Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics. 2004 Oct;5(7):895-931.</reference_text>
      <pubmed_id>15469410</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Testosterone</name>
        <accession>HMDB00234</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Testosterone</name>
        <accession>HMDB00234</accession>
      </metabolite>
      <reference>
        <reference_text>Zhang T, Zhu Y, Gunaratna C: Rapid and quantitative determination of metabolites from multiple cytochrome P450 probe substrates by gradient liquid chromatography-electrospray ionization-ion trap mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Nov 25;780(2):371-9.</reference_text>
        <pubmed_id>12401364</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aripiprazole</name>
        <accession>HMDB05042</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estradiol</name>
        <accession>HMDB00151</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estradiol</name>
        <accession>HMDB00151</accession>
      </metabolite>
      <reference>
        <reference_text>Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT: Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.</reference_text>
        <pubmed_id>12865317</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Caffeine</name>
        <accession>HMDB01847</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Caffeine</name>
        <accession>HMDB01847</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Codeine</name>
        <accession>HMDB04995</accession>
      </metabolite>
      <reference>
        <reference_text>Duquette PH, Peterson FJ, Crankshaw DL, Lindemann NJ, Holtzman JL: Studies of the metabolic N- and O-demethylation of [6-3H]codeine.  Drug Metab Dispos. 1983 Sep-Oct;11(5):477-80.</reference_text>
        <pubmed_id>6138234</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Codeine</name>
        <accession>HMDB04995</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ergocalciferol</name>
        <accession>HMDB00900</accession>
      </metabolite>
      <reference>
        <reference_text>Binkley N, Ramamurthy R, Krueger D: Low vitamin D status: definition, prevalence, consequences, and correction.  Endocrinol Metab Clin North Am. 2010 Jun;39(2):287-301, table of contents.</reference_text>
        <pubmed_id>20511052</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vitamin D3</name>
        <accession>HMDB00876</accession>
      </metabolite>
      <reference>
        <reference_text>Schuster I: Cytochromes P450 are essential players in the vitamin D signaling system.  Biochim Biophys Acta. 2011 Jan;1814(1):186-99. Epub 2010 Jul 7.</reference_text>
        <pubmed_id>20619365</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vitamin D3</name>
        <accession>HMDB00876</accession>
      </metabolite>
      <reference>
        <reference_text>Ohyama Y, Yamasaki T: Eight cytochrome P450s catalyze vitamin D metabolism.  Front Biosci. 2004 Sep 1;9:3007-18.</reference_text>
        <pubmed_id>15353333</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluvoxamine</name>
        <accession>HMDB14322</accession>
      </metabolite>
      <reference>
        <reference_text>Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69.</reference_text>
        <pubmed_id>8968657</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluvoxamine</name>
        <accession>HMDB14322</accession>
      </metabolite>
      <reference>
        <reference_text>Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression].  Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9.</reference_text>
        <pubmed_id>16910628</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluvoxamine</name>
        <accession>HMDB14322</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>L(-)-Nicotine pestanal</name>
        <accession>HMDB01934</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cevimeline</name>
        <accession>HMDB14331</accession>
      </metabolite>
      <reference>
        <reference_text>Washio T, Arisawa H, Kohsaka K, Yasuda H: Identification of human drug-metabolizing enzymes involved in the metabolism of SNI-2011. Biol Pharm Bull. 2001 Nov;24(11):1263-6.</reference_text>
        <pubmed_id>11725960</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cevimeline</name>
        <accession>HMDB14331</accession>
      </metabolite>
      <reference>
        <reference_text>Washio T, Kohsaka K, Arisawa H, Masunaga H: Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs. Arzneimittelforschung. 2003;53(1):26-33.</reference_text>
        <pubmed_id>12608011</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bortezomib</name>
        <accession>HMDB14334</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bortezomib</name>
        <accession>HMDB14334</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tramadol</name>
        <accession>HMDB14339</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluconazole</name>
        <accession>HMDB14342</accession>
      </metabolite>
      <reference>
        <reference_text>Niwa T, Shiraga T, Takagi A: Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005 Sep;28(9):1805-8.</reference_text>
        <pubmed_id>16141567</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluconazole</name>
        <accession>HMDB14342</accession>
      </metabolite>
      <reference>
        <reference_text>Kunze KL, Wienkers LC, Thummel KE, Trager WF: Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos. 1996 Apr;24(4):414-21.</reference_text>
        <pubmed_id>8801056</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluconazole</name>
        <accession>HMDB14342</accession>
      </metabolite>
      <reference>
        <reference_text>Sakaeda T, Iwaki K, Kakumoto M, Nishikawa M, Niwa T, Jin JS, Nakamura T, Nishiguchi K, Okamura N, Okumura K: Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol. 2005 Jun;57(6):759-64.</reference_text>
        <pubmed_id>15969931</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluconazole</name>
        <accession>HMDB14342</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Erythromycin</name>
        <accession>HMDB14344</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Erythromycin</name>
        <accession>HMDB14344</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.</reference_text>
        <pubmed_id>10490933</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dofetilide</name>
        <accession>HMDB14349</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Azithromycin</name>
        <accession>HMDB14352</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>7-Hydroxyticlopidine</name>
        <accession>HMDB13921</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>7-Hydroxyticlopidine</name>
        <accession>HMDB13921</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylcitalopram</name>
        <accession>HMDB14021</accession>
      </metabolite>
      <reference>
        <reference_text>Brosen K, Naranjo CA: Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol. 2001 Aug;11(4):275-83.</reference_text>
        <pubmed_id>11532381</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylcitalopram</name>
        <accession>HMDB14021</accession>
      </metabolite>
      <reference>
        <reference_text>Rasmussen BB, Brosen K: Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000 Apr;22(2):143-54.</reference_text>
        <pubmed_id>10774624</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylcitalopram</name>
        <accession>HMDB14021</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylcitalopram</name>
        <accession>HMDB14021</accession>
      </metabolite>
      <reference>
        <reference_text>Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes.  Xenobiotica. 1998 Dec;28(12):1203-53.</reference_text>
        <pubmed_id>9890159</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylcitalopram</name>
        <accession>HMDB14021</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyleletriptan</name>
        <accession>HMDB13919</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyleletriptan</name>
        <accession>HMDB13919</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nelfinavir</name>
        <accession>HMDB14365</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nelfinavir</name>
        <accession>HMDB14365</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Indinavir</name>
        <accession>HMDB14369</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Indinavir</name>
        <accession>HMDB14369</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Indinavir</name>
        <accession>HMDB14369</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.</reference_text>
        <pubmed_id>10490933</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lovastatin</name>
        <accession>HMDB14372</accession>
      </metabolite>
      <reference>
        <reference_text>Neuvonen PJ, Niemi M, Backman JT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.  Clin Pharmacol Ther. 2006 Dec;80(6):565-81.</reference_text>
        <pubmed_id>17178259</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lovastatin</name>
        <accession>HMDB14372</accession>
      </metabolite>
      <reference>
        <reference_text>Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH: Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.</reference_text>
        <pubmed_id>11523064</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lovastatin</name>
        <accession>HMDB14372</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lovastatin</name>
        <accession>HMDB14372</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Temazepam</name>
        <accession>HMDB14376</accession>
      </metabolite>
      <reference>
        <reference_text>Shou M, Mei Q, Ettore MW Jr, Dai R, Baillie TA, Rushmore TH: Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem J. 1999 Jun 15;340 ( Pt 3):845-53.</reference_text>
        <pubmed_id>10359672</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Temazepam</name>
        <accession>HMDB14376</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Reboxetine</name>
        <accession>HMDB14379</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>12-Hydroxynevirapine</name>
        <accession>HMDB13911</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>12-Hydroxynevirapine</name>
        <accession>HMDB13911</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxiconazole</name>
        <accession>HMDB14384</accession>
      </metabolite>
      <reference>
        <reference_text>Svecova L, Vrzal R, Burysek L, Anzenbacherova E, Cerveny L, Grim J, Trejtnar F, Kunes J, Pour M, Staud F, Anzenbacher P, Dvorak Z, Pavek P: Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression. Drug Metab Dispos. 2008 Feb;36(2):339-48. Epub 2007 Nov 12.</reference_text>
        <pubmed_id>17998298</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alclometasone</name>
        <accession>HMDB14385</accession>
      </metabolite>
      <reference>
        <reference_text>El-Sankary W, Bombail V, Gibson GG, Plant N: Glucocorticoid-mediated induction of CYP3A4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane X receptor response element. Drug Metab Dispos. 2002 Sep;30(9):1029-34.</reference_text>
        <pubmed_id>12167569</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alclometasone</name>
        <accession>HMDB14385</accession>
      </metabolite>
      <reference>
        <reference_text>Cooper BW, Cho TM, Thompson PM, Wallace AD: Phthalate induction of CYP3A4 is dependent on glucocorticoid regulation of PXR expression. Toxicol Sci. 2008 Jun;103(2):268-77. Epub 2008 Mar 10.</reference_text>
        <pubmed_id>18332045</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ziprasidone</name>
        <accession>HMDB14391</accession>
      </metabolite>
      <reference>
        <reference_text>Prakash C, Kamel A, Cui D, Whalen RD, Miceli JJ, Tweedie D: Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol. 2000;49 Suppl 1:35S-42S.</reference_text>
        <pubmed_id>10771452</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ziprasidone</name>
        <accession>HMDB14391</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ziprasidone</name>
        <accession>HMDB14391</accession>
      </metabolite>
      <reference>
        <reference_text>Nakamura H, Nakasa H, Ishii I, Ariyoshi N, Igarashi T, Ohmori S, Kitada M: Effects of endogenous steroids on CYP3A4-mediated drug metabolism by human liver microsomes. Drug Metab Dispos. 2002 May;30(5):534-40.</reference_text>
        <pubmed_id>11950784</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cabergoline</name>
        <accession>HMDB14393</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Acetyldapsone</name>
        <accession>HMDB13851</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Acetyldapsone</name>
        <accession>HMDB13851</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Acetyldapsone</name>
        <accession>HMDB13851</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.</reference_text>
        <pubmed_id>10490933</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3',4'-Dihydrodiol</name>
        <accession>HMDB13895</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxycycline</name>
        <accession>HMDB14399</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxycycline</name>
        <accession>HMDB14399</accession>
      </metabolite>
      <reference>
        <reference_text>Zhao XJ, Ishizaki T: A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (Ki) and type of inhibition. Eur J Drug Metab Pharmacokinet. 1999 Jul-Sep;24(3):272-8.</reference_text>
        <pubmed_id>10716067</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylstilbestrol</name>
        <accession>HMDB14400</accession>
      </metabolite>
      <reference>
        <reference_text>Qu YQ, Fang ZZ, Yang L, Gao ZM, Liang R, Zhu LL, Dong PP, Zhang YY, Ge GB, Wang LM: Reversible inhibition of four important human liver cytochrome P450 enzymes by diethylstilbestrol. Pharmazie. 2011 Mar;66(3):216-21.</reference_text>
        <pubmed_id>21553654</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfanilamide</name>
        <accession>HMDB14404</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ropinirole</name>
        <accession>HMDB14413</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ropinirole</name>
        <accession>HMDB14413</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isradipine</name>
        <accession>HMDB14415</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Theophylline</name>
        <accession>HMDB01889</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Argatroban</name>
        <accession>HMDB14423</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Disopyramide</name>
        <accession>HMDB14425</accession>
      </metabolite>
      <reference>
        <reference_text>Echizen H, Tanizaki M, Tatsuno J, Chiba K, Berwick T, Tani M, Gonzalez FJ, Ishizaki T: Identification of CYP3A4 as the enzyme involved in the mono-N-dealkylation of disopyramide enantiomers in humans. Drug Metab Dispos. 2000 Aug;28(8):937-44.</reference_text>
        <pubmed_id>10901704</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Disopyramide</name>
        <accession>HMDB14425</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Disopyramide</name>
        <accession>HMDB14425</accession>
      </metabolite>
      <reference>
        <reference_text>Zhang L, Fitzloff JF, Engel LC, Cook CS: Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide. Xenobiotica. 2001 Feb;31(2):73-83.</reference_text>
        <pubmed_id>11407536</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lidocaine</name>
        <accession>HMDB14426</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lidocaine</name>
        <accession>HMDB14426</accession>
      </metabolite>
      <reference>
        <reference_text>Wang JS, Backman JT, Taavitsainen P, Neuvonen PJ, Kivisto KT: Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos. 2000 Aug;28(8):959-65.</reference_text>
        <pubmed_id>10901707</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clemastine</name>
        <accession>HMDB14428</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atomoxetine</name>
        <accession>HMDB14434</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Etonogestrel</name>
        <accession>HMDB14439</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Morphine</name>
        <accession>HMDB14440</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ropivacaine</name>
        <accession>HMDB14441</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bupivacaine</name>
        <accession>HMDB14442</accession>
      </metabolite>
      <reference>
        <reference_text>Gantenbein M, Attolini L, Bruguerolle B, Villard PH, Puyoou F, Durand A, Lacarelle B, Hardwigsen J, Le-Treut YP: Oxidative metabolism of bupivacaine into pipecolylxylidine in humans is mainly catalyzed by CYP3A. Drug Metab Dispos. 2000 Apr;28(4):383-5.</reference_text>
        <pubmed_id>10725304</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bupivacaine</name>
        <accession>HMDB14442</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flucloxacillin</name>
        <accession>HMDB14446</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bexarotene</name>
        <accession>HMDB14452</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vindesine</name>
        <accession>HMDB14454</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vindesine</name>
        <accession>HMDB14454</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.</reference_text>
        <pubmed_id>10490933</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4-ene-Valproic acid</name>
        <accession>HMDB13897</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gefitinib</name>
        <accession>HMDB14462</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dihydroergotamine</name>
        <accession>HMDB14465</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluorometholone</name>
        <accession>HMDB14469</accession>
      </metabolite>
      <reference>
        <reference_text>El-Sankary W, Bombail V, Gibson GG, Plant N: Glucocorticoid-mediated induction of CYP3A4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane X receptor response element. Drug Metab Dispos. 2002 Sep;30(9):1029-34.</reference_text>
        <pubmed_id>12167569</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ipratropium bromide</name>
        <accession>HMDB14476</accession>
      </metabolite>
      <reference>
        <reference_text>Keam SJ, Keating GM: Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med. 2004;3(4):247-68.</reference_text>
        <pubmed_id>15350163</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methadone</name>
        <accession>HMDB14477</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methadone</name>
        <accession>HMDB14477</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methadone</name>
        <accession>HMDB14477</accession>
      </metabolite>
      <reference>
        <reference_text>Kharasch ED, Hoffer C, Whittington D, Sheffels P: Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004 Sep;76(3):250-69.</reference_text>
        <pubmed_id>15371986</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pimecrolimus</name>
        <accession>HMDB14481</accession>
      </metabolite>
      <reference>
        <reference_text>Zollinger M, Waldmeier F, Hartmann S, Zenke G, Zimmerlin AG, Glaenzel U, Baldeck JP, Schweitzer A, Berthier S, Moenius T, Grassberger MA: Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. Drug Metab Dispos. 2006 May;34(5):765-74. Epub 2006 Feb 7.</reference_text>
        <pubmed_id>16467136</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-Hydroxyomeprazole</name>
        <accession>HMDB14010</accession>
      </metabolite>
      <reference>
        <reference_text>Li XQ, Weidolf L, Simonsson R, Andersson TB: Enantiomer/enantiomer interactions between the S- and R- isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4. J Pharmacol Exp Ther. 2005 Nov;315(2):777-87. Epub 2005 Aug 10.</reference_text>
        <pubmed_id>16093273</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-Hydroxyomeprazole</name>
        <accession>HMDB14010</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-Hydroxyomeprazole</name>
        <accession>HMDB14010</accession>
      </metabolite>
      <reference>
        <reference_text>Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK: Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol. 1993 Jan;43(1):120-6.</reference_text>
        <pubmed_id>8423765</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-Hydroxyomeprazole</name>
        <accession>HMDB14010</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-Hydroxyomeprazole</name>
        <accession>HMDB14010</accession>
      </metabolite>
      <reference>
        <reference_text>Turpeinen M, Uusitalo J, Jalonen J, Pelkonen O: Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci. 2005 Jan;24(1):123-32.</reference_text>
        <pubmed_id>15626586</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pyrazinamide</name>
        <accession>HMDB14483</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terfenadine</name>
        <accession>HMDB14486</accession>
      </metabolite>
      <reference>
        <reference_text>Wang RW, Newton DJ, Liu N, Atkins WM, Lu AY: Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos. 2000 Mar;28(3):360-6.</reference_text>
        <pubmed_id>10681383</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terfenadine</name>
        <accession>HMDB14486</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terfenadine</name>
        <accession>HMDB14486</accession>
      </metabolite>
      <reference>
        <reference_text>Kishimoto W, Hiroi T, Sakai K, Funae Y, Igarashi T: Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol. 1997 Dec;98(3):273-92.</reference_text>
        <pubmed_id>9485522</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terfenadine</name>
        <accession>HMDB14486</accession>
      </metabolite>
      <reference>
        <reference_text>Nemeroff CB, DeVane CL, Pollock BG: Newer antidepressants and the cytochrome P450 system.  Am J Psychiatry. 1996 Mar;153(3):311-20.</reference_text>
        <pubmed_id>8610817</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diltiazem</name>
        <accession>HMDB14487</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diltiazem</name>
        <accession>HMDB14487</accession>
      </metabolite>
      <reference>
        <reference_text>Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA: Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.  Drug Metab Dispos. 2002 Aug;30(8):883-91.</reference_text>
        <pubmed_id>12124305</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfuzosin</name>
        <accession>HMDB14490</accession>
      </metabolite>
      <reference>
        <reference_text>Guay DR: Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. Am J Geriatr Pharmacother. 2004 Mar;2(1):14-23.</reference_text>
        <pubmed_id>15555475</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimethadione</name>
        <accession>HMDB14491</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimethadione</name>
        <accession>HMDB14491</accession>
      </metabolite>
      <reference>
        <reference_text>Tanaka E, Kurata N, Yasuhara H: Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6.</reference_text>
        <pubmed_id>14651673</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimethadione</name>
        <accession>HMDB14491</accession>
      </metabolite>
      <reference>
        <reference_text>Kurata N, Nishimura Y, Iwase M, Fischer NE, Tang BK, Inaba T, Yasuhara H: Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7.</reference_text>
        <pubmed_id>9879636</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clobazam</name>
        <accession>HMDB14493</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylergonovine</name>
        <accession>HMDB14497</accession>
      </metabolite>
      <reference>
        <reference_text>Moubarak AS, Rosenkrans CF Jr, Johnson ZB: Modulation of cytochrome P450 metabolism by ergonovine and dihydroergotamine.  Vet Hum Toxicol. 2003 Feb;45(1):6-9.</reference_text>
        <pubmed_id>12583687</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorzoxazone</name>
        <accession>HMDB14500</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aminoglutethimide</name>
        <accession>HMDB14501</accession>
      </metabolite>
      <reference>
        <reference_text>Santen RJ, Misbin RI: Aminoglutethimide: review of pharmacology and clinical use.  Pharmacotherapy. 1981 Sep-Oct;1(2):95-120.</reference_text>
        <pubmed_id>6765487</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mefloquine</name>
        <accession>HMDB14502</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfadiazine</name>
        <accession>HMDB14503</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinorelbine</name>
        <accession>HMDB14505</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Grepafloxacin</name>
        <accession>HMDB14509</accession>
      </metabolite>
      <reference>
        <reference_text>Pal D, Mitra AK: MDR- and CYP3A4-mediated drug-drug interactions.  J Neuroimmune Pharmacol. 2006 Sep;1(3):323-39. Epub 2006 Aug 2.</reference_text>
        <pubmed_id>18040809</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Grepafloxacin</name>
        <accession>HMDB14509</accession>
      </metabolite>
      <reference>
        <reference_text>Owens RC Jr: QT prolongation with antimicrobial agents: understanding the significance.  Drugs. 2004;64(10):1091-124.</reference_text>
        <pubmed_id>15139788</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levonorgestrel</name>
        <accession>HMDB14511</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mirtazapine</name>
        <accession>HMDB14514</accession>
      </metabolite>
      <reference>
        <reference_text>Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine.  CNS Drug Rev. 2001 Fall;7(3):249-64.</reference_text>
        <pubmed_id>11607047</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mirtazapine</name>
        <accession>HMDB14514</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mirtazapine</name>
        <accession>HMDB14514</accession>
      </metabolite>
      <reference>
        <reference_text>Stormer E, von Moltke LL, Shader RI, Greenblatt DJ: Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos. 2000 Oct;28(10):1168-75.</reference_text>
        <pubmed_id>10997935</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Palonosetron</name>
        <accession>HMDB14521</accession>
      </metabolite>
      <reference>
        <reference_text>Stoltz R, Parisi S, Shah A, Macciocchi A: Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers. Biopharm Drug Dispos. 2004 Nov;25(8):329-37.</reference_text>
        <pubmed_id>15378559</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Palonosetron</name>
        <accession>HMDB14521</accession>
      </metabolite>
      <reference>
        <reference_text>Stoltz R, Cyong JC, Shah A, Parisi S: Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J Clin Pharmacol. 2004 May;44(5):520-31.</reference_text>
        <pubmed_id>15102873</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mexiletine</name>
        <accession>HMDB14523</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Digoxin n</name>
        <accession>HMDB14534</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nimodipine</name>
        <accession>HMDB14537</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Progesterone</name>
        <accession>HMDB01830</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sorafenib</name>
        <accession>HMDB14542</accession>
      </metabolite>
      <reference>
        <reference_text>Gomo C, Coriat R, Faivre L, Mir O, Ropert S, Billemont B, Dauphin A, Tod M, Goldwasser F, Blanchet B: Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4. Epub 2010 Aug 13.</reference_text>
        <pubmed_id>20706860</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sorafenib</name>
        <accession>HMDB14542</accession>
      </metabolite>
      <reference>
        <reference_text>van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors.  Cancer Treat Rev. 2009 Dec;35(8):692-706. Epub 2009 Sep 5.</reference_text>
        <pubmed_id>19733976</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sorafenib</name>
        <accession>HMDB14542</accession>
      </metabolite>
      <reference>
        <reference_text>Flaherty KT, Lathia C, Frye RF, Schuchter L, Redlinger M, Rosen M, O'Dwyer PJ: Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8. Epub 2011 Feb 25.</reference_text>
        <pubmed_id>21350850</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Griseofulvin</name>
        <accession>HMDB14544</accession>
      </metabolite>
      <reference>
        <reference_text>Yasuda K, Ranade A, Venkataramanan R, Strom S, Chupka J, Ekins S, Schuetz E, Bachmann K: A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos. 2008 Aug;36(8):1689-97. Epub 2008 May 27.</reference_text>
        <pubmed_id>18505790</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nisoldipine</name>
        <accession>HMDB14545</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alpha-hydroxyalprazolam</name>
        <accession>HMDB13943</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alpha-hydroxyalprazolam</name>
        <accession>HMDB13943</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alpha-hydroxyalprazolam</name>
        <accession>HMDB13943</accession>
      </metabolite>
      <reference>
        <reference_text>Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA: Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.  Drug Metab Dispos. 2002 Aug;30(8):883-91.</reference_text>
        <pubmed_id>12124305</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promazine 5-sulfoxide</name>
        <accession>HMDB13938</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Promazine 5-sulfoxide</name>
        <accession>HMDB13938</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Famciclovir</name>
        <accession>HMDB14570</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prochlorperazine</name>
        <accession>HMDB14577</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimethoprim</name>
        <accession>HMDB14583</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Betamethasone</name>
        <accession>HMDB14586</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Teniposide</name>
        <accession>HMDB14587</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chloramphenicol</name>
        <accession>HMDB14589</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxylansoprazole</name>
        <accession>HMDB14008</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxylansoprazole</name>
        <accession>HMDB14008</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meperidine</name>
        <accession>HMDB14597</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meperidine</name>
        <accession>HMDB14597</accession>
      </metabolite>
      <reference>
        <reference_text>Ramirez J, Innocenti F, Schuetz EG, Flockhart DA, Relling MV, Santucci R, Ratain MJ: CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos. 2004 Sep;32(9):930-6.</reference_text>
        <pubmed_id>15319333</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinine</name>
        <accession>HMDB14611</accession>
      </metabolite>
      <reference>
        <reference_text>Zhao XJ, Yokoyama H, Chiba K, Wanwimolruk S, Ishizaki T: Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450. J Pharmacol Exp Ther. 1996 Dec;279(3):1327-34.</reference_text>
        <pubmed_id>8968357</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinine</name>
        <accession>HMDB14611</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinine</name>
        <accession>HMDB14611</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.</reference_text>
        <pubmed_id>10490933</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dronabinol</name>
        <accession>HMDB14613</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Montelukast</name>
        <accession>HMDB14614</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlordiazepoxide</name>
        <accession>HMDB14618</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorpromazine</name>
        <accession>HMDB14620</accession>
      </metabolite>
      <reference>
        <reference_text>Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data.  Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.</reference_text>
        <pubmed_id>11996015</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorpromazine</name>
        <accession>HMDB14620</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Raloxifene</name>
        <accession>HMDB14624</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxycelecoxib</name>
        <accession>HMDB13995</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxycelecoxib</name>
        <accession>HMDB13995</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dicloxacillin</name>
        <accession>HMDB14628</accession>
      </metabolite>
      <reference>
        <reference_text>Yasuda K, Ranade A, Venkataramanan R, Strom S, Chupka J, Ekins S, Schuetz E, Bachmann K: A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos. 2008 Aug;36(8):1689-97. Epub 2008 May 27.</reference_text>
        <pubmed_id>18505790</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Buspirone</name>
        <accession>HMDB14633</accession>
      </metabolite>
      <reference>
        <reference_text>Zhu M, Zhao W, Jimenez H, Zhang D, Yeola S, Dai R, Vachharajani N, Mitroka J: Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes.  Drug Metab Dispos. 2005 Apr;33(4):500-7. Epub 2005 Jan 7.</reference_text>
        <pubmed_id>15640381</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Buspirone</name>
        <accession>HMDB14633</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zidovudine</name>
        <accession>HMDB14638</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Darifenacin</name>
        <accession>HMDB14639</accession>
      </metabolite>
      <reference>
        <reference_text>Skerjanec A: The clinical pharmacokinetics of darifenacin.  Clin Pharmacokinet. 2006;45(4):325-50.</reference_text>
        <pubmed_id>16584282</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxycodone</name>
        <accession>HMDB14640</accession>
      </metabolite>
      <reference>
        <reference_text>Lalovic B, Phillips B, Risler LL, Howald W, Shen DD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54.</reference_text>
        <pubmed_id>15039299</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flutamide</name>
        <accession>HMDB14642</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cimetidine</name>
        <accession>HMDB14644</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Haloperidol</name>
        <accession>HMDB14645</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Haloperidol</name>
        <accession>HMDB14645</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Haloperidol</name>
        <accession>HMDB14645</accession>
      </metabolite>
      <reference>
        <reference_text>Kalgutkar AS, Taylor TJ, Venkatakrishnan K, Isin EM: Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab Dispos. 2003 Mar;31(3):243-9.</reference_text>
        <pubmed_id>12584149</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ritonavir</name>
        <accession>HMDB14646</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ritonavir</name>
        <accession>HMDB14646</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Albendazole</name>
        <accession>HMDB14659</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Caspofungin</name>
        <accession>HMDB14661</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lercanidipine</name>
        <accession>HMDB14669</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Erlotinib</name>
        <accession>HMDB14671</accession>
      </metabolite>
      <reference>
        <reference_text>van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors.  Cancer Treat Rev. 2009 Dec;35(8):692-706. Epub 2009 Sep 5.</reference_text>
        <pubmed_id>19733976</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Erlotinib</name>
        <accession>HMDB14671</accession>
      </metabolite>
      <reference>
        <reference_text>Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, Gobburu J, Booth B, Benson K, Leighton J, Hsieh LS, Chidambaram N, Zimmerman P, Pazdur R: Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res. 2005 Sep 15;11(18):6414-21.</reference_text>
        <pubmed_id>16166415</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Erlotinib</name>
        <accession>HMDB14671</accession>
      </metabolite>
      <reference>
        <reference_text>Li J, Zhao M, He P, Hidalgo M, Baker SD: Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7.</reference_text>
        <pubmed_id>17575239</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Erlotinib</name>
        <accession>HMDB14671</accession>
      </metabolite>
      <reference>
        <reference_text>Hamilton M, Wolf JL, Rusk J, Beard SE, Clark GM, Witt K, Cagnoni PJ: Effects of smoking on the pharmacokinetics of erlotinib.  Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2166-71.</reference_text>
        <pubmed_id>16609030</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4-Hydroxycyclophosphamide</name>
        <accession>HMDB13856</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4-Hydroxycyclophosphamide</name>
        <accession>HMDB13856</accession>
      </metabolite>
      <reference>
        <reference_text>Preiss R, Schmidt R, Baumann F, Hanschmann H, Hauss J, Geissler F, Pahlig H, Ratzewiss B: Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol. 2002 Jul;128(7):385-92. Epub 2002 Jun 11.</reference_text>
        <pubmed_id>12136253</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4-Hydroxycyclophosphamide</name>
        <accession>HMDB13856</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ciprofloxacin</name>
        <accession>HMDB14677</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Toremifene</name>
        <accession>HMDB14679</accession>
      </metabolite>
      <reference>
        <reference_text>Taneja SS, Smith MR, Dalton JT, Raghow S, Barnette G, Steiner M, Veverka KA: Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert Opin Investig Drugs. 2006 Mar;15(3):293-305.</reference_text>
        <pubmed_id>16503765</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Toremifene</name>
        <accession>HMDB14679</accession>
      </metabolite>
      <reference>
        <reference_text>Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ: Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Clin Pharmacol Ther. 1998 Dec;64(6):648-54.</reference_text>
        <pubmed_id>9871429</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Toremifene</name>
        <accession>HMDB14679</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Wen B, Ma L, Zhu M: Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67. Epub 2008 Feb 14.</reference_text>
        <pubmed_id>18359012</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nortriptyline</name>
        <accession>HMDB14680</accession>
      </metabolite>
      <reference>
        <reference_text>Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. J Clin Pharmacol. 1999 Jun;39(6):567-77.</reference_text>
        <pubmed_id>10354960</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vincristine</name>
        <accession>HMDB14681</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pyridostigmine</name>
        <accession>HMDB14685</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Adinazolam</name>
        <accession>HMDB14686</accession>
      </metabolite>
      <reference>
        <reference_text>Venkatakrishnan K, von Moltke LL, Duan SX, Fleishaker JC, Shader RI, Greenblatt DJ: Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. J Pharm Pharmacol. 1998 Mar;50(3):265-74.</reference_text>
        <pubmed_id>9600717</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Adinazolam</name>
        <accession>HMDB14686</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zafirlukast</name>
        <accession>HMDB14689</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zafirlukast</name>
        <accession>HMDB14689</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methoxsalen</name>
        <accession>HMDB14693</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bosentan</name>
        <accession>HMDB14699</accession>
      </metabolite>
      <reference>
        <reference_text>Dingemanse J, Schaarschmidt D, van Giersbergen PL: Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin. Clin Pharmacokinet. 2003;42(3):293-301.</reference_text>
        <pubmed_id>12603176</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bosentan</name>
        <accession>HMDB14699</accession>
      </metabolite>
      <reference>
        <reference_text>Dingemanse J, van Giersbergen PL: Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.  Clin Pharmacokinet. 2004;43(15):1089-115.</reference_text>
        <pubmed_id>15568889</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bosentan</name>
        <accession>HMDB14699</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bosentan</name>
        <accession>HMDB14699</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbamazepine</name>
        <accession>HMDB14704</accession>
      </metabolite>
      <reference>
        <reference_text>Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8.</reference_text>
        <pubmed_id>18537577</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbamazepine</name>
        <accession>HMDB14704</accession>
      </metabolite>
      <reference>
        <reference_text>Levy RH: Cytochrome P450 isozymes and antiepileptic drug interactions.  Epilepsia. 1995;36 Suppl 5:S8-13.</reference_text>
        <pubmed_id>8806399</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbamazepine</name>
        <accession>HMDB14704</accession>
      </metabolite>
      <reference>
        <reference_text>Cazali N, Tran A, Treluyer JM, Rey E, d'Athis P, Vincent J, Pons G: Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. Br J Clin Pharmacol. 2003 Nov;56(5):526-36.</reference_text>
        <pubmed_id>14651727</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbamazepine</name>
        <accession>HMDB14704</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cephalexin</name>
        <accession>HMDB14707</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vinblastine</name>
        <accession>HMDB14710</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.</reference_text>
        <pubmed_id>10490933</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Voriconazole</name>
        <accession>HMDB14720</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Voriconazole</name>
        <accession>HMDB14720</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Enalapril</name>
        <accession>HMDB14722</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4'-Hydroxydiclofenac</name>
        <accession>HMDB13974</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4'-Hydroxydiclofenac</name>
        <accession>HMDB13974</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluticasone Propionate</name>
        <accession>HMDB14726</accession>
      </metabolite>
      <reference>
        <reference_text>Pearce RE, Leeder JS, Kearns GL: Biotransformation of fluticasone: in vitro characterization.  Drug Metab Dispos. 2006 Jun;34(6):1035-40. Epub 2006 Mar 24.</reference_text>
        <pubmed_id>16565171</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fluticasone Propionate</name>
        <accession>HMDB14726</accession>
      </metabolite>
      <reference>
        <reference_text>Murai T, Reilly CA, Ward RM, Yost GS: The inhaled glucocorticoid fluticasone propionate efficiently inactivates cytochrome P450 3A5, a predominant lung P450 enzyme. Chem Res Toxicol. 2010 Aug 16;23(8):1356-64.</reference_text>
        <pubmed_id>20707410</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lisuride</name>
        <accession>HMDB14727</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lisuride</name>
        <accession>HMDB14727</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethosuximide</name>
        <accession>HMDB14731</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Thiopental</name>
        <accession>HMDB14737</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ivermectin</name>
        <accession>HMDB14740</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cisapride</name>
        <accession>HMDB14742</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cisapride</name>
        <accession>HMDB14742</accession>
      </metabolite>
      <reference>
        <reference_text>Pearce RE, Gotschall RR, Kearns GL, Leeder JS: Cytochrome P450 Involvement in the biotransformation of cisapride and racemic norcisapride in vitro: differential activity of individual human CYP3A isoforms. Drug Metab Dispos. 2001 Dec;29(12):1548-54.</reference_text>
        <pubmed_id>11717173</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nafcillin</name>
        <accession>HMDB14745</accession>
      </metabolite>
      <reference>
        <reference_text>Yasuda K, Ranade A, Venkataramanan R, Strom S, Chupka J, Ekins S, Schuetz E, Bachmann K: A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos. 2008 Aug;36(8):1689-97. Epub 2008 May 27.</reference_text>
        <pubmed_id>18505790</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nafcillin</name>
        <accession>HMDB14745</accession>
      </metabolite>
      <reference>
        <reference_text>Kim KY, Frey RJ, Epplen K, Foruhari F: Interaction between warfarin and nafcillin: case report and review of the literature. Pharmacotherapy. 2007 Oct;27(10):1467-70.</reference_text>
        <pubmed_id>17896903</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nafcillin</name>
        <accession>HMDB14745</accession>
      </metabolite>
      <reference>
        <reference_text>Lang CC, Jamal SK, Mohamed Z, Mustafa MR, Mustafa AM, Lee TC: Evidence of an interaction between nifedipine and nafcillin in humans.  Br J Clin Pharmacol. 2003 Jun;55(6):588-90.</reference_text>
        <pubmed_id>12814453</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chloroquine</name>
        <accession>HMDB14746</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bisoprolol</name>
        <accession>HMDB14750</accession>
      </metabolite>
      <reference>
        <reference_text>Horikiri Y, Suzuki T, Mizobe M: Pharmacokinetics and metabolism of bisoprolol enantiomers in humans.  J Pharm Sci. 1998 Mar;87(3):289-94.</reference_text>
        <pubmed_id>9523980</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bisoprolol</name>
        <accession>HMDB14750</accession>
      </metabolite>
      <reference>
        <reference_text>Horikiri Y, Suzuki T, Mizobe M: Stereoselective metabolism of bisoprolol enantiomers in dogs and humans.  Life Sci. 1998;63(13):1097-108.</reference_text>
        <pubmed_id>9763205</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bisoprolol</name>
        <accession>HMDB14750</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rifabutin</name>
        <accession>HMDB14753</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rifabutin</name>
        <accession>HMDB14753</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.</reference_text>
        <pubmed_id>10490933</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paramethadione</name>
        <accession>HMDB14755</accession>
      </metabolite>
      <reference>
        <reference_text>Tanaka E, Kurata N, Yasuhara H: Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther. 2003 Dec;28(6):493-6.</reference_text>
        <pubmed_id>14651673</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paramethadione</name>
        <accession>HMDB14755</accession>
      </metabolite>
      <reference>
        <reference_text>Kurata N, Nishimura Y, Iwase M, Fischer NE, Tang BK, Inaba T, Yasuhara H: Trimethadione metabolism by human liver cytochrome P450: evidence for the involvement of CYP2E1. Xenobiotica. 1998 Nov;28(11):1041-7.</reference_text>
        <pubmed_id>9879636</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-desmethylimatinib</name>
        <accession>HMDB13862</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nicardipine</name>
        <accession>HMDB14760</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Efavirenz</name>
        <accession>HMDB14763</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clorazepate</name>
        <accession>HMDB14766</accession>
      </metabolite>
      <reference>
        <reference_text>Dresser GK, Spence JD, Bailey DG: Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000 Jan;38(1):41-57.</reference_text>
        <pubmed_id>10668858</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clorazepate</name>
        <accession>HMDB14766</accession>
      </metabolite>
      <reference>
        <reference_text>Sachs B, Erdmann S, Al-Masaoudi T, Merk HF: In vitro drug allergy detection system incorporating human liver microsomes in chlorazepate-induced skin rash: drug-specific proliferation associated with interleukin-5 secretion. Br J Dermatol. 2001 Feb;144(2):316-20.</reference_text>
        <pubmed_id>11251565</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prednisone</name>
        <accession>HMDB14773</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clofibrate</name>
        <accession>HMDB14774</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Astemizole</name>
        <accession>HMDB14775</accession>
      </metabolite>
      <reference>
        <reference_text>Nicolas JM, Whomsley R, Collart P, Roba J: In vitro inhibition of human liver drug metabolizing enzymes by second generation antihistamines. Chem Biol Interact. 1999 Nov 15;123(1):63-79.</reference_text>
        <pubmed_id>10597902</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Astemizole</name>
        <accession>HMDB14775</accession>
      </metabolite>
      <reference>
        <reference_text>Matsumoto S, Yamazoe Y: Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine. Br J Clin Pharmacol. 2001 Feb;51(2):133-42.</reference_text>
        <pubmed_id>11259984</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Astemizole</name>
        <accession>HMDB14775</accession>
      </metabolite>
      <reference>
        <reference_text>Cvetkovic RS, Goa KL: Lopinavir/ritonavir: a review of its use in the management of HIV infection.  Drugs. 2003;63(8):769-802.</reference_text>
        <pubmed_id>12662125</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Astemizole</name>
        <accession>HMDB14775</accession>
      </metabolite>
      <reference>
        <reference_text>Goto A, Adachi Y, Inaba A, Nakajima H, Kobayashi H, Sakai K: Identification of human p450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its inhibitory effect on enzyme activity. Biol Pharm Bull. 2004 May;27(5):684-90.</reference_text>
        <pubmed_id>15133245</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Astemizole</name>
        <accession>HMDB14775</accession>
      </metabolite>
      <reference>
        <reference_text>Goto A, Ueda K, Inaba A, Nakajima H, Kobayashi H, Sakai K: Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.</reference_text>
        <pubmed_id>15684493</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Astemizole</name>
        <accession>HMDB14775</accession>
      </metabolite>
      <reference>
        <reference_text>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank.  Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</reference_text>
        <pubmed_id>10592235</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Astemizole</name>
        <accession>HMDB14775</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mebendazole</name>
        <accession>HMDB14781</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propoxyphene</name>
        <accession>HMDB14785</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trazodone</name>
        <accession>HMDB14794</accession>
      </metabolite>
      <reference>
        <reference_text>Rotzinger S, Fang J, Baker GB: Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos. 1998 Jun;26(6):572-5.</reference_text>
        <pubmed_id>9616194</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trazodone</name>
        <accession>HMDB14794</accession>
      </metabolite>
      <reference>
        <reference_text>Kalgutkar AS, Henne KR, Lame ME, Vaz AD, Collin C, Soglia JR, Zhao SX, Hop CE: Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4. Chem Biol Interact. 2005 Jun 30;155(1-2):10-20. Epub 2005 Apr 18.</reference_text>
        <pubmed_id>15978881</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trazodone</name>
        <accession>HMDB14794</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>O-Desmethylverapamil (D-702)</name>
        <accession>HMDB13961</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.</reference_text>
        <pubmed_id>10490933</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Histamine Phosphate</name>
        <accession>HMDB14805</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aprepitant</name>
        <accession>HMDB14811</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aprepitant</name>
        <accession>HMDB14811</accession>
      </metabolite>
      <reference>
        <reference_text>Sanchez RI, Wang RW, Newton DJ, Bakhtiar R, Lu P, Chiu SH, Evans DC, Huskey SE: Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004 Nov;32(11):1287-92. Epub 2004 Aug 10.</reference_text>
        <pubmed_id>15304427</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Galantamine</name>
        <accession>HMDB14812</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Desta Z, Ward BA, Soukhova NV, Flockhart DA: Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75. Epub 2004 May 24.</reference_text>
        <pubmed_id>15159443</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethyltamoxifen</name>
        <accession>HMDB13866</accession>
      </metabolite>
      <reference>
        <reference_text>Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA: Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.  Drug Metab Dispos. 2002 Aug;30(8):883-91.</reference_text>
        <pubmed_id>12124305</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>E-3179</name>
        <accession>HMDB13846</accession>
      </metabolite>
      <reference>
        <reference_text>Song JC, White CM: Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists. Pharmacotherapy. 2000 Feb;20(2):130-9.</reference_text>
        <pubmed_id>10678291</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>E-3179</name>
        <accession>HMDB13846</accession>
      </metabolite>
      <reference>
        <reference_text>Sica DA, Gehr TW, Ghosh S: Clinical pharmacokinetics of losartan.  Clin Pharmacokinet. 2005;44(8):797-814.</reference_text>
        <pubmed_id>16029066</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>E-3179</name>
        <accession>HMDB13846</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>E-3179</name>
        <accession>HMDB13846</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>S-6-Hydroxywarfarin</name>
        <accession>HMDB13880</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>S-6-Hydroxywarfarin</name>
        <accession>HMDB13880</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Foti RS, Rock DA, Wienkers LC, Wahlstrom JL: Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos. 2010 Jun;38(6):981-7. Epub 2010 Mar 4.</reference_text>
        <pubmed_id>20203109</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes.  Xenobiotica. 1998 Dec;28(12):1203-53.</reference_text>
        <pubmed_id>9890159</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, Zhang Q, Huang M, Xu A: Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab. 2004 Oct;5(5):415-42.</reference_text>
        <pubmed_id>15544435</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA: Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.  Drug Metab Dispos. 2002 Aug;30(8):883-91.</reference_text>
        <pubmed_id>12124305</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Galetin A, Clarke SE, Houston JB: Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos. 2002 Dec;30(12):1512-22.</reference_text>
        <pubmed_id>12433827</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Midazolam</name>
        <accession>HMDB14821</accession>
      </metabolite>
      <reference>
        <reference_text>Obach RS, Reed-Hagen AE: Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos. 2002 Jul;30(7):831-7.</reference_text>
        <pubmed_id>12065442</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flurazepam</name>
        <accession>HMDB14828</accession>
      </metabolite>
      <reference>
        <reference_text>Capello S, Henderson L, DeGrazia F, Liberato D, Garland W, Town C: The effect of the cytochrome P-450 suicide inactivator, 1-aminobenzotriazole, on the in vivo metabolism and pharmacologic activity of flurazepam. Drug Metab Dispos. 1990 Mar-Apr;18(2):190-6.</reference_text>
        <pubmed_id>1971572</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flurazepam</name>
        <accession>HMDB14828</accession>
      </metabolite>
      <reference>
        <reference_text>Linder CD, Renaud NA, Hutzler JM: Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos. 2009 Jan;37(1):10-3. Epub 2008 Oct 20.</reference_text>
        <pubmed_id>18936109</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Daunorubicin</name>
        <accession>HMDB14832</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ergotamine</name>
        <accession>HMDB14834</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Eplerenone</name>
        <accession>HMDB14838</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amprenavir</name>
        <accession>HMDB14839</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Amprenavir</name>
        <accession>HMDB14839</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methazolamide</name>
        <accession>HMDB14841</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Delavirdine</name>
        <accession>HMDB14843</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Delavirdine</name>
        <accession>HMDB14843</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Delavirdine</name>
        <accession>HMDB14843</accession>
      </metabolite>
      <reference>
        <reference_text>Voorman RL, Maio SM, Payne NA, Zhao Z, Koeplinger KA, Wang X: Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A. J Pharmacol Exp Ther. 1998 Oct;287(1):381-8.</reference_text>
        <pubmed_id>9765359</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tamsulosin</name>
        <accession>HMDB14844</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sufentanil</name>
        <accession>HMDB14846</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norethindrone</name>
        <accession>HMDB14855</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Azatadine</name>
        <accession>HMDB14857</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Imiquimod</name>
        <accession>HMDB14862</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimipramine</name>
        <accession>HMDB14864</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nateglinide</name>
        <accession>HMDB14869</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nateglinide</name>
        <accession>HMDB14869</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentamidine</name>
        <accession>HMDB14876</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydrocortisone</name>
        <accession>HMDB14879</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydrocortisone</name>
        <accession>HMDB14879</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.</reference_text>
        <pubmed_id>10490933</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxyzileuton</name>
        <accession>HMDB13968</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroxyzileuton</name>
        <accession>HMDB13968</accession>
      </metabolite>
      <reference>
        <reference_text>Machinist JM, Mayer MD, Shet MS, Ferrero JL, Rodrigues AD: Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. Drug Metab Dispos. 1995 Oct;23(10):1163-74.</reference_text>
        <pubmed_id>8654206</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Modafinil</name>
        <accession>HMDB14883</accession>
      </metabolite>
      <reference>
        <reference_text>Robertson P Jr, Hellriegel ET: Clinical pharmacokinetic profile of modafinil.  Clin Pharmacokinet. 2003;42(2):123-37.</reference_text>
        <pubmed_id>12537513</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Modafinil</name>
        <accession>HMDB14883</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Carbinoxamine</name>
        <accession>HMDB14886</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Epinastine</name>
        <accession>HMDB14889</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tranylcypromine</name>
        <accession>HMDB14890</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dolasetron</name>
        <accession>HMDB14895</accession>
      </metabolite>
      <reference>
        <reference_text>Sanwald P, David M, Dow J: Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos. 1996 May;24(5):602-9.</reference_text>
        <pubmed_id>8723743</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>2-Oxoclopidogrel</name>
        <accession>HMDB13929</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>2-Oxoclopidogrel</name>
        <accession>HMDB13929</accession>
      </metabolite>
      <reference>
        <reference_text>Saw J, Steinhubl SR, Berger PB, Kereiakes DJ, Serebruany VL, Brennan D, Topol EJ: Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation. 2003 Aug 26;108(8):921-4. Epub 2003 Aug 18.</reference_text>
        <pubmed_id>12925453</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>2-Oxoclopidogrel</name>
        <accession>HMDB13929</accession>
      </metabolite>
      <reference>
        <reference_text>Neubauer H, Gunesdogan B, Hanefeld C, Spiecker M, Mugge A: Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function--a flow cytometry study. Eur Heart J. 2003 Oct;24(19):1744-9.</reference_text>
        <pubmed_id>14522569</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>2-Oxoclopidogrel</name>
        <accession>HMDB13929</accession>
      </metabolite>
      <reference>
        <reference_text>Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, Guyer KE, Tait AR, Bates ER: Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004 Jan 20;109(2):166-71. Epub 2004 Jan 5.</reference_text>
        <pubmed_id>14707025</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>2-Oxoclopidogrel</name>
        <accession>HMDB13929</accession>
      </metabolite>
      <reference>
        <reference_text>Mukherjee D, Kline-Rogers E, Fang J, Munir K, Eagle KA: Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome. Heart. 2005 Jan;91(1):23-6.</reference_text>
        <pubmed_id>15604326</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>2-Oxoclopidogrel</name>
        <accession>HMDB13929</accession>
      </metabolite>
      <reference>
        <reference_text>Poulsen TS, Vinholt P, Mickley H, Korsholm L, Kristensen SR, Damkier P: Existence of a clinically relevant interaction between clopidogrel and HMG-CoA reductase inhibitors? Re-evaluating the evidence. Basic Clin Pharmacol Toxicol. 2005 Feb;96(2):103-10.</reference_text>
        <pubmed_id>15679472</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>2-Oxoclopidogrel</name>
        <accession>HMDB13929</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>2-Oxoclopidogrel</name>
        <accession>HMDB13929</accession>
      </metabolite>
      <reference>
        <reference_text>Clarke TA, Waskell LA: The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003 Jan;31(1):53-9.</reference_text>
        <pubmed_id>12485953</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tetracycline</name>
        <accession>HMDB14897</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Irinotecan</name>
        <accession>HMDB14900</accession>
      </metabolite>
      <reference>
        <reference_text>Ramesh M, Ahlawat P, Srinivas NR: Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010 Jan;24(1):104-23.</reference_text>
        <pubmed_id>19852077</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Irinotecan</name>
        <accession>HMDB14900</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Irinotecan</name>
        <accession>HMDB14900</accession>
      </metabolite>
      <reference>
        <reference_text>Kuhn JG: Pharmacology of irinotecan.  Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):39-42.</reference_text>
        <pubmed_id>9726089</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methimazole</name>
        <accession>HMDB14901</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Olopatadine</name>
        <accession>HMDB14906</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydrocortamate</name>
        <accession>HMDB14907</accession>
      </metabolite>
      <reference>
        <reference_text>El-Sankary W, Bombail V, Gibson GG, Plant N: Glucocorticoid-mediated induction of CYP3A4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane X receptor response element. Drug Metab Dispos. 2002 Sep;30(9):1029-34.</reference_text>
        <pubmed_id>12167569</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Etoposide</name>
        <accession>HMDB14911</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Etoposide</name>
        <accession>HMDB14911</accession>
      </metabolite>
      <reference>
        <reference_text>Kawashiro T, Yamashita K, Zhao XJ, Koyama E, Tani M, Chiba K, Ishizaki T: A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.</reference_text>
        <pubmed_id>9732391</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxcarbazepine</name>
        <accession>HMDB14914</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Roxithromycin</name>
        <accession>HMDB14916</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenelzine</name>
        <accession>HMDB14918</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Primidone</name>
        <accession>HMDB14932</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfentanil</name>
        <accession>HMDB14940</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alfentanil</name>
        <accession>HMDB14940</accession>
      </metabolite>
      <reference>
        <reference_text>Klees TM, Sheffels P, Dale O, Kharasch ED: Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes.  Drug Metab Dispos. 2005 Mar;33(3):303-11. Epub 2004 Nov 22.</reference_text>
        <pubmed_id>15557344</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Indapamide</name>
        <accession>HMDB14946</accession>
      </metabolite>
      <reference>
        <reference_text>Sun H, Moore C, Dansette PM, Kumar S, Halpert JR, Yost GS: Dehydrogenation of the indoline-containing drug 4-chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide (indapamide) by CYP3A4: correlation with in silico predictions. Drug Metab Dispos. 2009 Mar;37(3):672-84. Epub 2008 Dec 12.</reference_text>
        <pubmed_id>19074530</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenylbutazone</name>
        <accession>HMDB14950</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fentanyl</name>
        <accession>HMDB14951</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fentanyl</name>
        <accession>HMDB14951</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.</reference_text>
        <pubmed_id>10490933</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meloxicam</name>
        <accession>HMDB14952</accession>
      </metabolite>
      <reference>
        <reference_text>Chesne C, Guyomard C, Guillouzo A, Schmid J, Ludwig E, Sauter T: Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4.  Xenobiotica. 1998 Jan;28(1):1-13.</reference_text>
        <pubmed_id>9493314</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meloxicam</name>
        <accession>HMDB14952</accession>
      </metabolite>
      <reference>
        <reference_text>Ludwig E, Schmid J, Beschke K, Ebner T: Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther. 1999 Jul;290(1):1-8.</reference_text>
        <pubmed_id>10381752</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Meloxicam</name>
        <accession>HMDB14952</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>4-Hydroxypropofol</name>
        <accession>HMDB14018</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acetazolamide</name>
        <accession>HMDB14957</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tadalafil</name>
        <accession>HMDB14958</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Disulfiram</name>
        <accession>HMDB14960</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mifepristone</name>
        <accession>HMDB14972</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxazepam</name>
        <accession>HMDB14980</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-O-Desmethyldonepezil</name>
        <accession>HMDB13958</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>5-O-Desmethyldonepezil</name>
        <accession>HMDB13958</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clofazimine</name>
        <accession>HMDB14983</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Perphenazine</name>
        <accession>HMDB14988</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Temozolomide</name>
        <accession>HMDB14991</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorphenesin</name>
        <accession>HMDB14994</accession>
      </metabolite>
      <reference>
        <reference_text>Medina-Diaz IM, Arteaga-Illan G, de Leon MB, Cisneros B, Sierra-Santoyo A, Vega L, Gonzalez FJ, Elizondo G: Pregnane X receptor-dependent induction of the CYP3A4 gene by o,p'-1,1,1,-trichloro-2,2-bis (p-chlorophenyl)ethane. Drug Metab Dispos. 2007 Jan;35(1):95-102. Epub 2006 Oct 11.</reference_text>
        <pubmed_id>17035600</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorphenesin</name>
        <accession>HMDB14994</accession>
      </metabolite>
      <reference>
        <reference_text>Petersen MS, Halling J, Damkier P, Nielsen F, Grandjean P, Weihe P, Brosen K: Polychlorinated biphenyl (PCB) induction of CYP3A4 enzyme activity in healthy Faroese adults. Toxicol Appl Pharmacol. 2007 Oct 15;224(2):202-6. Epub 2007 Jul 14.</reference_text>
        <pubmed_id>17692354</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terbinafine</name>
        <accession>HMDB14995</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Terbinafine</name>
        <accession>HMDB14995</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prednisolone</name>
        <accession>HMDB14998</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vardenafil</name>
        <accession>HMDB15000</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrolimus</name>
        <accession>HMDB15002</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tacrolimus</name>
        <accession>HMDB15002</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.</reference_text>
        <pubmed_id>10490933</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzphetamine</name>
        <accession>HMDB15003</accession>
      </metabolite>
      <reference>
        <reference_text>Seree EJ, Pisano PJ, Placidi M, Rahmani R, Barra YA: Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol. 1993;7(2):69-75.</reference_text>
        <pubmed_id>8486332</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dorzolamide</name>
        <accession>HMDB15007</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Conivaptan</name>
        <accession>HMDB15010</accession>
      </metabolite>
      <reference>
        <reference_text>Ali F, Raufi MA, Washington B, Ghali JK: Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].  Cardiovasc Drug Rev. 2007 Fall;25(3):261-79.</reference_text>
        <pubmed_id>17919259</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sirolimus</name>
        <accession>HMDB15015</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sirolimus</name>
        <accession>HMDB15015</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.</reference_text>
        <pubmed_id>10490933</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomifene</name>
        <accession>HMDB15020</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isosorbide Dinitrate</name>
        <accession>HMDB15021</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Granisetron</name>
        <accession>HMDB15026</accession>
      </metabolite>
      <reference>
        <reference_text>Tan M: Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2003 Sep;4(9):1563-71.</reference_text>
        <pubmed_id>12943486</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Granisetron</name>
        <accession>HMDB15026</accession>
      </metabolite>
      <reference>
        <reference_text>Janicki PK: Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit. 2005 Oct;11(10):RA322-8. Epub 2005 Sep 26.</reference_text>
        <pubmed_id>16192915</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Granisetron</name>
        <accession>HMDB15026</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triazolam</name>
        <accession>HMDB15034</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Triazolam</name>
        <accession>HMDB15034</accession>
      </metabolite>
      <reference>
        <reference_text>Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA: Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.  Drug Metab Dispos. 2002 Aug;30(8):883-91.</reference_text>
        <pubmed_id>12124305</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethanol</name>
        <accession>HMDB00108</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tiagabine</name>
        <accession>HMDB15042</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cocaine</name>
        <accession>HMDB15043</accession>
      </metabolite>
      <reference>
        <reference_text>Ladona MG, Gonzalez ML, Rane A, Peter RM, de la Torre R: Cocaine metabolism in human fetal and adult liver microsomes is related to cytochrome P450 3A expression. Life Sci. 2000 Dec 15;68(4):431-43.</reference_text>
        <pubmed_id>11205892</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cocaine</name>
        <accession>HMDB15043</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Ludwig E, Schmid J, Beschke K, Ebner T: Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'-methylhydroxylation by quinidine and hydroquinidine in vitro. J Pharmacol Exp Ther. 1999 Jul;290(1):1-8.</reference_text>
        <pubmed_id>10381752</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinidine</name>
        <accession>HMDB15044</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.</reference_text>
        <pubmed_id>10490933</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Nakasa H, Komiya M, Ohmori S, Rikihisa T, Kiuchi M, Kitada M: Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide. Mol Pharmacol. 1993 Jul;44(1):216-21.</reference_text>
        <pubmed_id>8341274</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Schulze-Bonhage A: Zonisamide in the treatment of epilepsy.  Expert Opin Pharmacother. 2010 Jan;11(1):115-26.</reference_text>
        <pubmed_id>20001433</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Zaccara G, Specchio LM: Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat. 2009;5:249-59. Epub 2009 May 20.</reference_text>
        <pubmed_id>19557119</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M: Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur J Clin Pharmacol. 1998 Apr;54(2):177-83.</reference_text>
        <pubmed_id>9626925</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tinidazole</name>
        <accession>HMDB15047</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Repaglinide</name>
        <accession>HMDB15048</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Repaglinide</name>
        <accession>HMDB15048</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Repaglinide</name>
        <accession>HMDB15048</accession>
      </metabolite>
      <reference>
        <reference_text>Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT: CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol. 2003 Sep;56(3):305-14.</reference_text>
        <pubmed_id>12919179</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Metronidazole</name>
        <accession>HMDB15052</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Almotriptan</name>
        <accession>HMDB15054</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Almotriptan</name>
        <accession>HMDB15054</accession>
      </metabolite>
      <reference>
        <reference_text>Salva M, Jansat JM, Martinez-Tobed A, Palacios JM: Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.</reference_text>
        <pubmed_id>12642466</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Almotriptan</name>
        <accession>HMDB15054</accession>
      </metabolite>
      <reference>
        <reference_text>McEnroe JD, Fleishaker JC: Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine. Clin Pharmacokinet. 2005;44(3):237-46.</reference_text>
        <pubmed_id>15762767</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cyclobenzaprine</name>
        <accession>HMDB15060</accession>
      </metabolite>
      <reference>
        <reference_text>Wang RW, Liu L, Cheng H: Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91.</reference_text>
        <pubmed_id>8818577</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cyclobenzaprine</name>
        <accession>HMDB15060</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenoxybenzamine</name>
        <accession>HMDB15061</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tipranavir</name>
        <accession>HMDB15067</accession>
      </metabolite>
      <reference>
        <reference_text>Temesgen Z, Feinberg J: Tipranavir: a new option for the treatment of drug-resistant HIV infection.  Clin Infect Dis. 2007 Sep 15;45(6):761-9. Epub 2007 Aug 7.</reference_text>
        <pubmed_id>17712762</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tipranavir</name>
        <accession>HMDB15067</accession>
      </metabolite>
      <reference>
        <reference_text>Luna B, Townsend MU: Tipranavir: the first nonpeptidic protease inhibitor for the treatment of protease resistance. Clin Ther. 2007 Nov;29(11):2309-18.</reference_text>
        <pubmed_id>18158073</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tipranavir</name>
        <accession>HMDB15067</accession>
      </metabolite>
      <reference>
        <reference_text>Li F, Wang L, Guo GL, Ma X: Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos. 2010 May;38(5):871-8. Epub 2010 Jan 26.</reference_text>
        <pubmed_id>20103582</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tipranavir</name>
        <accession>HMDB15067</accession>
      </metabolite>
      <reference>
        <reference_text>Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La-Beck NM, Drulak M, Sabo JP, Castles MA, Macgregor TR, Kashuba AD: A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010 Jun;87(6):735-42. Epub 2010 Feb 10.</reference_text>
        <pubmed_id>20147896</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Salmeterol</name>
        <accession>HMDB15073</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zalcitabine</name>
        <accession>HMDB15078</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenprocoumon</name>
        <accession>HMDB15081</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Phenprocoumon</name>
        <accession>HMDB15081</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fulvestrant</name>
        <accession>HMDB15082</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Felbamate</name>
        <accession>HMDB15084</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isoniazid</name>
        <accession>HMDB15086</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydrocodone</name>
        <accession>HMDB15091</accession>
      </metabolite>
      <reference>
        <reference_text>Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA: CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2004 Mar;57(3):287-97.</reference_text>
        <pubmed_id>14998425</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methylprednisolone</name>
        <accession>HMDB15094</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zaleplon</name>
        <accession>HMDB15097</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Alosetron</name>
        <accession>HMDB15104</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ezetimibe</name>
        <accession>HMDB15108</accession>
      </metabolite>
      <reference>
        <reference_text>Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB: Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.</reference_text>
        <pubmed_id>15871634</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Telithromycin</name>
        <accession>HMDB15111</accession>
      </metabolite>
      <reference>
        <reference_text>Bearden DT, Neuhauser MM, Garey KW: Telithromycin: an oral ketolide for respiratory infections.  Pharmacotherapy. 2001 Oct;21(10):1204-22.</reference_text>
        <pubmed_id>11601667</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Telithromycin</name>
        <accession>HMDB15111</accession>
      </metabolite>
      <reference>
        <reference_text>Zhanel GG, Walters M, Noreddin A, Vercaigne LM, Wierzbowski A, Embil JM, Gin AS, Douthwaite S, Hoban DJ: The ketolides: a critical review.  Drugs. 2002;62(12):1771-804.</reference_text>
        <pubmed_id>12149046</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Telithromycin</name>
        <accession>HMDB15111</accession>
      </metabolite>
      <reference>
        <reference_text>Reed M, Wall GC, Shah NP, Heun JM, Hicklin GA: Verapamil toxicity resulting from a probable interaction with telithromycin.  Ann Pharmacother. 2005 Feb;39(2):357-60. Epub 2004 Dec 14.</reference_text>
        <pubmed_id>15598962</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Telithromycin</name>
        <accession>HMDB15111</accession>
      </metabolite>
      <reference>
        <reference_text>Shi J, Chapel S, Montay G, Hardy P, Barrett JS, Sica D, Swan SK, Noveck R, Leroy B, Bhargava VO: Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment. Int J Clin Pharmacol Ther. 2005 Mar;43(3):123-33.</reference_text>
        <pubmed_id>15792396</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Telithromycin</name>
        <accession>HMDB15111</accession>
      </metabolite>
      <reference>
        <reference_text>Nguyen M, Chung EP: Telithromycin: the first ketolide antimicrobial.  Clin Ther. 2005 Aug;27(8):1144-63.</reference_text>
        <pubmed_id>16199242</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Telithromycin</name>
        <accession>HMDB15111</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>17a-Ethynylestradiol</name>
        <accession>HMDB01926</accession>
      </metabolite>
      <reference>
        <reference_text>Wang B, Sanchez RI, Franklin RB, Evans DC, Huskey SE: The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004 Nov;32(11):1209-12. Epub 2004 Aug 10.</reference_text>
        <pubmed_id>15304426</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ramelteon</name>
        <accession>HMDB15115</accession>
      </metabolite>
      <reference>
        <reference_text>Obach RS, Ryder TF: Metabolism of ramelteon in human liver microsomes and correlation with the effect of fluvoxamine on ramelteon pharmacokinetics. Drug Metab Dispos. 2010 Aug;38(8):1381-91. Epub 2010 May 17.</reference_text>
        <pubmed_id>20478852</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cytarabine</name>
        <accession>HMDB15122</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rivastigmine</name>
        <accession>HMDB15124</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Exemestane</name>
        <accession>HMDB15125</accession>
      </metabolite>
      <reference>
        <reference_text>Robinson A: A review of the use of exemestane in early breast cancer.  Ther Clin Risk Manag. 2009 Feb;5(1):91-8. Epub 2009 Mar 26.</reference_text>
        <pubmed_id>19436613</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Exemestane</name>
        <accession>HMDB15125</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Doxorubicin</name>
        <accession>HMDB15132</accession>
      </metabolite>
      <reference>
        <reference_text>Lu H, Chen CS, Waxman DJ: Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer. Cancer Gene Ther. 2009 May;16(5):393-404. Epub 2008 Nov 14.</reference_text>
        <pubmed_id>19011599</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levobupivacaine</name>
        <accession>HMDB15137</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Letrozole</name>
        <accession>HMDB15141</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tioconazole</name>
        <accession>HMDB15142</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Busulfan</name>
        <accession>HMDB15143</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Metyrapone</name>
        <accession>HMDB15146</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cinacalcet</name>
        <accession>HMDB15147</accession>
      </metabolite>
      <reference>
        <reference_text>Padhi D, Harris R: Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride.  Clin Pharmacokinet. 2009;48(5):303-11. doi: 10.2165/00003088-200948050-00002.</reference_text>
        <pubmed_id>19566113</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cinacalcet</name>
        <accession>HMDB15147</accession>
      </metabolite>
      <reference>
        <reference_text>Dong BJ: Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.  Clin Ther. 2005 Nov;27(11):1725-51.</reference_text>
        <pubmed_id>16368445</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Glyburide</name>
        <accession>HMDB15151</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Glyburide</name>
        <accession>HMDB15151</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Guanfacine</name>
        <accession>HMDB15153</accession>
      </metabolite>
      <reference>
        <reference_text>Clement B, Demesmaeker M: Microsomal catalyzed N-hydroxylation of guanfacine and reduction of N-hydroxyguanfacine. Arch Pharm (Weinheim). 1997 Oct;330(9-10):303-6.</reference_text>
        <pubmed_id>9396389</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Guanfacine</name>
        <accession>HMDB15153</accession>
      </metabolite>
      <reference>
        <reference_text>Guillouzo A, Le Bigot JF, Guguen-Guillouzo C, Kiechel JR: Presence of phase I and phase II drug metabolizing enzymes in cultured human foetal hepatocytes. Biochem Pharmacol. 1982 Jul 15;31(14):2427-30.</reference_text>
        <pubmed_id>6751332</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Isosorbide Mononitrate</name>
        <accession>HMDB15155</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Felodipine</name>
        <accession>HMDB15158</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Felodipine</name>
        <accession>HMDB15158</accession>
      </metabolite>
      <reference>
        <reference_text>Galetin A, Clarke SE, Houston JB: Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos. 2002 Dec;30(12):1512-22.</reference_text>
        <pubmed_id>12433827</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methoxyflurane</name>
        <accession>HMDB15162</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>SR 49498</name>
        <accession>HMDB13845</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Topotecan</name>
        <accession>HMDB15164</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Probenecid</name>
        <accession>HMDB15166</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Dealkylated tolterodine</name>
        <accession>HMDB13972</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Dealkylated tolterodine</name>
        <accession>HMDB13972</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Dealkylated tolterodine</name>
        <accession>HMDB13972</accession>
      </metabolite>
      <reference>
        <reference_text>Postlind H, DanielsonA, Lindgren A, Andersson SH: Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos. 1998 Apr;26(4):289-93.</reference_text>
        <pubmed_id>9531513</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Selegiline</name>
        <accession>HMDB15171</accession>
      </metabolite>
      <reference>
        <reference_text>Benetton SA, Fang C, Yang YO, Alok R, Year M, Lin CC, Yeh LT: P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. Drug Metab Pharmacokinet. 2007 Apr;22(2):78-87.</reference_text>
        <pubmed_id>17495414</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fenofibrate</name>
        <accession>HMDB15173</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rifampin</name>
        <accession>HMDB15179</accession>
      </metabolite>
      <reference>
        <reference_text>Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD: Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos. 2007 Oct;35(10):1853-9. Epub 2007 Jul 16.</reference_text>
        <pubmed_id>17639026</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rifampin</name>
        <accession>HMDB15179</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ergoloid mesylate</name>
        <accession>HMDB15183</accession>
      </metabolite>
      <reference>
        <reference_text>Althaus M, Retzow A, Castell JV, Gomez-Lechon MJ, Amalou Z, Rose T, Appel K: In vitro identification of the cytochrome P450 isoform responsible for the metabolism of alpha-dihydroergocryptine. Xenobiotica. 2000 Nov;30(11):1033-45.</reference_text>
        <pubmed_id>11197065</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nitrendipine</name>
        <accession>HMDB15187</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Praziquantel</name>
        <accession>HMDB15191</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Norfloxacin</name>
        <accession>HMDB15192</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxybutynin</name>
        <accession>HMDB15195</accession>
      </metabolite>
      <reference>
        <reference_text>Yaich M, Popon M, Medard Y, Aigrain EJ: In-vitro cytochrome P450 dependent metabolism of oxybutynin to N-deethyloxybutynin in humans. Pharmacogenetics. 1998 Oct;8(5):449-51.</reference_text>
        <pubmed_id>9825837</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxybutynin</name>
        <accession>HMDB15195</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Glipizide</name>
        <accession>HMDB15200</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clonazepam</name>
        <accession>HMDB15201</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mequitazine</name>
        <accession>HMDB15204</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atazanavir</name>
        <accession>HMDB15205</accession>
      </metabolite>
      <reference>
        <reference_text>Le Tiec C, Barrail A, Goujard C, Taburet AM: Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.  Clin Pharmacokinet. 2005;44(10):1035-50.</reference_text>
        <pubmed_id>16176117</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atazanavir</name>
        <accession>HMDB15205</accession>
      </metabolite>
      <reference>
        <reference_text>Busti AJ, Hall RG, Margolis DM: Atazanavir for the treatment of human immunodeficiency virus infection.  Pharmacotherapy. 2004 Dec;24(12):1732-47.</reference_text>
        <pubmed_id>15585441</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Atazanavir</name>
        <accession>HMDB15205</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Perhexiline</name>
        <accession>HMDB15207</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Orlistat</name>
        <accession>HMDB15215</accession>
      </metabolite>
      <reference>
        <reference_text>Novotna A, Doricakova A, Vrzal R, Maurel P, Pavek P, Dvorak Z: Investigation of Orlistat effects on PXR activation and CYP3A4 expression in primary human hepatocytes and human intestinal LS174T cells. Eur J Pharm Sci. 2010 Oct 9;41(2):276-80. Epub 2010 Jul 3.</reference_text>
        <pubmed_id>20599501</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pilocarpine</name>
        <accession>HMDB15217</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Primaquine</name>
        <accession>HMDB15219</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dimethyl sulfoxide</name>
        <accession>HMDB02151</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>6-Hydroxyfluvastatin</name>
        <accession>HMDB14037</accession>
      </metabolite>
      <reference>
        <reference_text>Fischer V, Johanson L, Heitz F, Tullman R, Graham E, Baldeck JP, Robinson WT: The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Dispos. 1999 Mar;27(3):410-6.</reference_text>
        <pubmed_id>10064574</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>6-Hydroxyfluvastatin</name>
        <accession>HMDB14037</accession>
      </metabolite>
      <reference>
        <reference_text>Toda T, Eliasson E, Ask B, Inotsume N, Rane A: Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes. Basic Clin Pharmacol Toxicol. 2009 Nov;105(5):327-32. Epub 2009 Aug 6.</reference_text>
        <pubmed_id>19663817</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>6-Hydroxyfluvastatin</name>
        <accession>HMDB14037</accession>
      </metabolite>
      <reference>
        <reference_text>Scripture CD, Pieper JA: Clinical pharmacokinetics of fluvastatin.  Clin Pharmacokinet. 2001;40(4):263-81.</reference_text>
        <pubmed_id>11368292</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>6-Hydroxyfluvastatin</name>
        <accession>HMDB14037</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>6-Hydroxyfluvastatin</name>
        <accession>HMDB14037</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rosuvastatin</name>
        <accession>HMDB15230</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pimozide</name>
        <accession>HMDB15232</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinacrine</name>
        <accession>HMDB15235</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Sharma B, Henderson DC: Sibutramine: current status as an anti-obesity drug and its future perspectives.  Expert Opin Pharmacother. 2008 Aug;9(12):2161-73.</reference_text>
        <pubmed_id>18671470</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sibutramine</name>
        <accession>HMDB15237</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Miconazole</name>
        <accession>HMDB15242</accession>
      </metabolite>
      <reference>
        <reference_text>Sakaeda T, Iwaki K, Kakumoto M, Nishikawa M, Niwa T, Jin JS, Nakamura T, Nishiguchi K, Okamura N, Okumura K: Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol. 2005 Jun;57(6):759-64.</reference_text>
        <pubmed_id>15969931</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Miconazole</name>
        <accession>HMDB15242</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nifedipine</name>
        <accession>HMDB15247</accession>
      </metabolite>
      <reference>
        <reference_text>Foti RS, Rock DA, Wienkers LC, Wahlstrom JL: Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos. 2010 Jun;38(6):981-7. Epub 2010 Mar 4.</reference_text>
        <pubmed_id>20203109</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nifedipine</name>
        <accession>HMDB15247</accession>
      </metabolite>
      <reference>
        <reference_text>Lee SJ, Bell DA, Coulter SJ, Ghanayem B, Goldstein JA: Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype. J Pharmacol Exp Ther. 2005 Apr;313(1):302-9. Epub 2005 Jan 5.</reference_text>
        <pubmed_id>15634941</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nifedipine</name>
        <accession>HMDB15247</accession>
      </metabolite>
      <reference>
        <reference_text>Pelkonen O, Maenpaa J, Taavitsainen P, Rautio A, Raunio H: Inhibition and induction of human cytochrome P450 (CYP) enzymes.  Xenobiotica. 1998 Dec;28(12):1203-53.</reference_text>
        <pubmed_id>9890159</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nifedipine</name>
        <accession>HMDB15247</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nifedipine</name>
        <accession>HMDB15247</accession>
      </metabolite>
      <reference>
        <reference_text>Galetin A, Clarke SE, Houston JB: Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. Drug Metab Dispos. 2002 Dec;30(12):1512-22.</reference_text>
        <pubmed_id>12433827</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dutasteride</name>
        <accession>HMDB15258</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Econazole</name>
        <accession>HMDB15259</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bicalutamide</name>
        <accession>HMDB15260</accession>
      </metabolite>
      <reference>
        <reference_text>Cockshott ID: Bicalutamide: clinical pharmacokinetics and metabolism.  Clin Pharmacokinet. 2004;43(13):855-78.</reference_text>
        <pubmed_id>15509184</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Proguanil</name>
        <accession>HMDB15263</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pioglitazone</name>
        <accession>HMDB15264</accession>
      </metabolite>
      <reference>
        <reference_text>Jaakkola T, Laitila J, Neuvonen PJ, Backman JT: Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):44-51.</reference_text>
        <pubmed_id>16867170</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pioglitazone</name>
        <accession>HMDB15264</accession>
      </metabolite>
      <reference>
        <reference_text>Sahi J, Black CB, Hamilton GA, Zheng X, Jolley S, Rose KA, Gilbert D, LeCluyse EL, Sinz MW: Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.</reference_text>
        <pubmed_id>12642470</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pioglitazone</name>
        <accession>HMDB15264</accession>
      </metabolite>
      <reference>
        <reference_text>Nowak SN, Edwards DJ, Clarke A, Anderson GD, Jaber LA: Pioglitazone: effect on CYP3A4 activity.  J Clin Pharmacol. 2002 Dec;42(12):1299-302.</reference_text>
        <pubmed_id>12463723</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pioglitazone</name>
        <accession>HMDB15264</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pioglitazone</name>
        <accession>HMDB15264</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>8-Hydroxycarvedilol</name>
        <accession>HMDB13946</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>8-Hydroxycarvedilol</name>
        <accession>HMDB13946</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfinpyrazone</name>
        <accession>HMDB15269</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sulfinpyrazone</name>
        <accession>HMDB15269</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nefazodone</name>
        <accession>HMDB15280</accession>
      </metabolite>
      <reference>
        <reference_text>Davis R, Whittington R, Bryson HM: Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997 Apr;53(4):608-36.</reference_text>
        <pubmed_id>9098663</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nefazodone</name>
        <accession>HMDB15280</accession>
      </metabolite>
      <reference>
        <reference_text>DeVane CL, Donovan JL, Liston HL, Markowitz JS, Cheng KT, Risch SC, Willard L: Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharmacol. 2004 Feb;24(1):4-10.</reference_text>
        <pubmed_id>14709940</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nefazodone</name>
        <accession>HMDB15280</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nefazodone</name>
        <accession>HMDB15280</accession>
      </metabolite>
      <reference>
        <reference_text>von Moltke LL, Greenblatt DJ, Granda BW, Grassi JM, Schmider J, Harmatz JS, Shader RI: Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berl). 1999 Jul;145(1):113-22.</reference_text>
        <pubmed_id>10445380</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Desipramine</name>
        <accession>HMDB15282</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluoroacetic acid</name>
        <accession>HMDB14118</accession>
      </metabolite>
      <reference>
        <reference_text>Restrepo JG, Garcia-Martin E, Martinez C, Agundez JA: Polymorphic drug metabolism in anaesthesia.  Curr Drug Metab. 2009 Mar;10(3):236-46.</reference_text>
        <pubmed_id>19442086</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trifluoroacetic acid</name>
        <accession>HMDB14118</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cilostazol</name>
        <accession>HMDB15297</accession>
      </metabolite>
      <reference>
        <reference_text>Suri A, Forbes WP, Bramer SL: Effects of CYP3A inhibition on the metabolism of cilostazol.  Clin Pharmacokinet. 1999;37 Suppl 2:61-8.</reference_text>
        <pubmed_id>10702888</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Itraconazole</name>
        <accession>HMDB15298</accession>
      </metabolite>
      <reference>
        <reference_text>Niwa T, Shiraga T, Takagi A: Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005 Sep;28(9):1805-8.</reference_text>
        <pubmed_id>16141567</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Itraconazole</name>
        <accession>HMDB15298</accession>
      </metabolite>
      <reference>
        <reference_text>Sakaeda T, Iwaki K, Kakumoto M, Nishikawa M, Niwa T, Jin JS, Nakamura T, Nishiguchi K, Okamura N, Okumura K: Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol. 2005 Jun;57(6):759-64.</reference_text>
        <pubmed_id>15969931</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Itraconazole</name>
        <accession>HMDB15298</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Arsenic trioxide</name>
        <accession>HMDB15300</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Guanethidine</name>
        <accession>HMDB15301</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Orphenadrine</name>
        <accession>HMDB15304</accession>
      </metabolite>
      <reference>
        <reference_text>Roos PH, Mahnke A: Metabolite complex formation of orphenadrine with cytochrome P450. Involvement of CYP2C11 and CYP3A isozymes. Biochem Pharmacol. 1996 Jul 12;52(1):73-84.</reference_text>
        <pubmed_id>8678911</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Podofilox</name>
        <accession>HMDB15310</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3-Dechloroethylifosfamide</name>
        <accession>HMDB13858</accession>
      </metabolite>
      <reference>
        <reference_text>Lokiec F: Ifosfamide: pharmacokinetic properties for central nervous system metastasis prevention. Ann Oncol. 2006 May;17 Suppl 4:iv33-6.</reference_text>
        <pubmed_id>16702183</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3-Dechloroethylifosfamide</name>
        <accession>HMDB13858</accession>
      </metabolite>
      <reference>
        <reference_text>Chen CS, Jounaidi Y, Waxman DJ: Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450. Drug Metab Dispos. 2005 Sep;33(9):1261-7. Epub 2005 May 26.</reference_text>
        <pubmed_id>15919850</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3-Dechloroethylifosfamide</name>
        <accession>HMDB13858</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3-Dechloroethylifosfamide</name>
        <accession>HMDB13858</accession>
      </metabolite>
      <reference>
        <reference_text>Roy P, Yu LJ, Crespi CL, Waxman DJ: Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.</reference_text>
        <pubmed_id>10348794</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3-Dechloroethylifosfamide</name>
        <accession>HMDB13858</accession>
      </metabolite>
      <reference>
        <reference_text>Preiss R, Schmidt R, Baumann F, Hanschmann H, Hauss J, Geissler F, Pahlig H, Ratzewiss B: Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide. J Cancer Res Clin Oncol. 2002 Jul;128(7):385-92. Epub 2002 Jun 11.</reference_text>
        <pubmed_id>12136253</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3-Dechloroethylifosfamide</name>
        <accession>HMDB13858</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Propafenone</name>
        <accession>HMDB15313</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Naloxone</name>
        <accession>HMDB15314</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Domperidone</name>
        <accession>HMDB15315</accession>
      </metabolite>
      <reference>
        <reference_text>Chang SY, Fancher RM, Zhang H, Gan J: Mechanism-based inhibition of human cytochrome P4503A4 by domperidone.  Xenobiotica. 2010 Feb;40(2):138-45.</reference_text>
        <pubmed_id>20082577</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Domperidone</name>
        <accession>HMDB15315</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Domperidone</name>
        <accession>HMDB15315</accession>
      </metabolite>
      <reference>
        <reference_text>Simard C, Michaud V, Gibbs B, Masse R, Lessard E, Turgeon J: Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica. 2004 Nov-Dec;34(11-12):1013-23.</reference_text>
        <pubmed_id>15801545</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pergolide</name>
        <accession>HMDB15317</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pergolide</name>
        <accession>HMDB15317</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clindamycin</name>
        <accession>HMDB15321</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxymorphone</name>
        <accession>HMDB15323</accession>
      </metabolite>
      <reference>
        <reference_text>Gronlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K: Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010 Jul;70(1):78-87.</reference_text>
        <pubmed_id>20642550</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxymorphone</name>
        <accession>HMDB15323</accession>
      </metabolite>
      <reference>
        <reference_text>Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, Rossier MF, Hochstrasser D, Dayer P, Desmeules JA: The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol. 2010 Jun;160(4):907-18.</reference_text>
        <pubmed_id>20590587</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxymorphone</name>
        <accession>HMDB15323</accession>
      </metabolite>
      <reference>
        <reference_text>Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD: Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006 May;79(5):461-79.</reference_text>
        <pubmed_id>16678548</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Oxymorphone</name>
        <accession>HMDB15323</accession>
      </metabolite>
      <reference>
        <reference_text>Adams M, Pieniaszek HJ Jr, Gammaitoni AR, Ahdieh H: Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways.  J Clin Pharmacol. 2005 Mar;45(3):337-45.</reference_text>
        <pubmed_id>15703368</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Brinzolamide</name>
        <accession>HMDB15325</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estramustine</name>
        <accession>HMDB15327</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zopiclone</name>
        <accession>HMDB15329</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zopiclone</name>
        <accession>HMDB15329</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zopiclone</name>
        <accession>HMDB15329</accession>
      </metabolite>
      <reference>
        <reference_text>Lalovic B, Phillips B, Risler LL, Howald W, Shen DD: Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54.</reference_text>
        <pubmed_id>15039299</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromocriptine</name>
        <accession>HMDB15331</accession>
      </metabolite>
      <reference>
        <reference_text>Fernando H, Halpert JR, Davydov DR: Resolution of multiple substrate binding sites in cytochrome P450 3A4: the stoichiometry of the enzyme-substrate complexes probed by FRET and Job's titration. Biochemistry. 2006 Apr 4;45(13):4199-209.</reference_text>
        <pubmed_id>16566594</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromocriptine</name>
        <accession>HMDB15331</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromocriptine</name>
        <accession>HMDB15331</accession>
      </metabolite>
      <reference>
        <reference_text>Nath A, Grinkova YV, Sligar SG, Atkins WM: Ligand binding to cytochrome P450 3A4 in phospholipid bilayer nanodiscs: the effect of model membranes. J Biol Chem. 2007 Sep 28;282(39):28309-20. Epub 2007 Jun 15.</reference_text>
        <pubmed_id>17573349</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromocriptine</name>
        <accession>HMDB15331</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rifapentine</name>
        <accession>HMDB15332</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mitoxantrone</name>
        <accession>HMDB15335</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lomustine</name>
        <accession>HMDB15337</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clarithromycin</name>
        <accession>HMDB15342</accession>
      </metabolite>
      <reference>
        <reference_text>Zuckerman JM, Qamar F, Bono BR: Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect Dis Clin North Am. 2009 Dec;23(4):997-1026, ix-x.</reference_text>
        <pubmed_id>19909895</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clarithromycin</name>
        <accession>HMDB15342</accession>
      </metabolite>
      <reference>
        <reference_text>[No authors listed]Clarithromycin.  Tuberculosis (Edinb). 2008 Mar;88(2):92-5.</reference_text>
        <pubmed_id>18486039</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clarithromycin</name>
        <accession>HMDB15342</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clarithromycin</name>
        <accession>HMDB15342</accession>
      </metabolite>
      <reference>
        <reference_text>Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA: Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.  Drug Metab Dispos. 2002 Aug;30(8):883-91.</reference_text>
        <pubmed_id>12124305</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Estazolam</name>
        <accession>HMDB15346</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Finasteride  e</name>
        <accession>HMDB15347</accession>
      </metabolite>
      <reference>
        <reference_text>Huskey SW, Dean DC, Miller RR, Rasmusson GH, Chiu SH: Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metab Dispos. 1995 Oct;23(10):1126-35.</reference_text>
        <pubmed_id>8654202</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Finasteride  e</name>
        <accession>HMDB15347</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Anastrozole</name>
        <accession>HMDB15348</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Halofantrine</name>
        <accession>HMDB15349</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dantrolene</name>
        <accession>HMDB15350</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rifaximin</name>
        <accession>HMDB15351</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Budesonide</name>
        <accession>HMDB15353</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Budesonide</name>
        <accession>HMDB15353</accession>
      </metabolite>
      <reference>
        <reference_text>Jonsson G, Astrom A, Andersson P: Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver.  Drug Metab Dispos. 1995 Jan;23(1):137-42.</reference_text>
        <pubmed_id>7720517</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aminophylline</name>
        <accession>HMDB15354</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levomethadyl Acetate</name>
        <accession>HMDB15358</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Levomethadyl Acetate</name>
        <accession>HMDB15358</accession>
      </metabolite>
      <reference>
        <reference_text>Oda Y, Kharasch ED: Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation. J Pharmacol Exp Ther. 2001 Sep;298(3):1021-32.</reference_text>
        <pubmed_id>11504799</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paclitaxel</name>
        <accession>HMDB15360</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Saquinavir</name>
        <accession>HMDB15362</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Saquinavir</name>
        <accession>HMDB15362</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Saquinavir</name>
        <accession>HMDB15362</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.</reference_text>
        <pubmed_id>10490933</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexamethasone</name>
        <accession>HMDB15364</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dexamethasone</name>
        <accession>HMDB15364</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.</reference_text>
        <pubmed_id>10490933</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sevoflurane</name>
        <accession>HMDB15366</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Gemfibrozil</name>
        <accession>HMDB15371</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clomipramine</name>
        <accession>HMDB15372</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trimeprazine</name>
        <accession>HMDB15376</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Docetaxel</name>
        <accession>HMDB15378</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ergonovine</name>
        <accession>HMDB15383</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ergonovine</name>
        <accession>HMDB15383</accession>
      </metabolite>
      <reference>
        <reference_text>Moubarak AS, Rosenkrans CF Jr, Johnson ZB: Modulation of cytochrome P450 metabolism by ergonovine and dihydroergotamine.  Vet Hum Toxicol. 2003 Feb;45(1):6-9.</reference_text>
        <pubmed_id>12583687</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dasatinib</name>
        <accession>HMDB15384</accession>
      </metabolite>
      <reference>
        <reference_text>van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors.  Cancer Treat Rev. 2009 Dec;35(8):692-706. Epub 2009 Sep 5.</reference_text>
        <pubmed_id>19733976</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dasatinib</name>
        <accession>HMDB15384</accession>
      </metabolite>
      <reference>
        <reference_text>Wang L, Christopher LJ, Cui D, Li W, Iyer R, Humphreys WG, Zhang D: Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos. 2008 Sep;36(9):1828-39. Epub 2008 Jun 12.</reference_text>
        <pubmed_id>18556438</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Aliskiren</name>
        <accession>HMDB15387</accession>
      </metabolite>
      <reference>
        <reference_text>Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP: Clinical pharmacokinetics and pharmacodynamics of aliskiren.  Clin Pharmacokinet. 2008;47(8):515-31.</reference_text>
        <pubmed_id>18611061</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lapatinib</name>
        <accession>HMDB15388</accession>
      </metabolite>
      <reference>
        <reference_text>Medina PJ, Goodin S: Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008 Aug;30(8):1426-47.</reference_text>
        <pubmed_id>18803986</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lapatinib</name>
        <accession>HMDB15388</accession>
      </metabolite>
      <reference>
        <reference_text>van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors.  Cancer Treat Rev. 2009 Dec;35(8):692-706. Epub 2009 Sep 5.</reference_text>
        <pubmed_id>19733976</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lapatinib</name>
        <accession>HMDB15388</accession>
      </metabolite>
      <reference>
        <reference_text>Teng WC, Oh JW, New LS, Wahlin MD, Nelson SD, Ho HK, Chan EC: Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.  Mol Pharmacol. 2010 Oct;78(4):693-703. Epub 2010 Jul 12.</reference_text>
        <pubmed_id>20624855</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sitagliptin</name>
        <accession>HMDB15390</accession>
      </metabolite>
      <reference>
        <reference_text>Scheen AJ: Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.  Diabetes Obes Metab. 2010 Aug;12(8):648-58.</reference_text>
        <pubmed_id>20590741</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Posaconazole</name>
        <accession>HMDB15392</accession>
      </metabolite>
      <reference>
        <reference_text>Nagappan V, Deresinski S: Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis. 2007 Dec 15;45(12):1610-7.</reference_text>
        <pubmed_id>18190324</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Posaconazole</name>
        <accession>HMDB15392</accession>
      </metabolite>
      <reference>
        <reference_text>Kharuzhyk SA, Matskevich SA, Filjustin AE, Bogushevich EV, Ugolkova SA: Survey of computed tomography doses and establishment of national diagnostic reference levels in the Republic of Belarus. Radiat Prot Dosimetry. 2010 Apr-May;139(1-3):367-70. Epub 2010 Feb 24.</reference_text>
        <pubmed_id>20181649</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Posaconazole</name>
        <accession>HMDB15392</accession>
      </metabolite>
      <reference>
        <reference_text>Kwon DS, Mylonakis E: Posaconazole: a new broad-spectrum antifungal agent.  Expert Opin Pharmacother. 2007 Jun;8(8):1167-78.</reference_text>
        <pubmed_id>17516880</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Darunavir</name>
        <accession>HMDB15393</accession>
      </metabolite>
      <reference>
        <reference_text>McKeage K, Perry CM, Keam SJ: Darunavir: a review of its use in the management of HIV infection in adults.  Drugs. 2009;69(4):477-503. doi: 10.2165/00003495-200969040-00007.</reference_text>
        <pubmed_id>19323590</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Darunavir</name>
        <accession>HMDB15393</accession>
      </metabolite>
      <reference>
        <reference_text>Tremblay CL: Combating HIV resistance - focus on darunavir.  Ther Clin Risk Manag. 2008 Aug;4(4):759-66.</reference_text>
        <pubmed_id>19209258</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paliperidone</name>
        <accession>HMDB15396</accession>
      </metabolite>
      <reference>
        <reference_text>Gunes A, Spina E, Dahl ML, Scordo MG: ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther Drug Monit. 2008 Oct;30(5):628-33.</reference_text>
        <pubmed_id>18708991</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydralazine</name>
        <accession>HMDB15400</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rolitetracycline</name>
        <accession>HMDB15414</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fosamprenavir</name>
        <accession>HMDB15416</accession>
      </metabolite>
      <reference>
        <reference_text>Wire MB, Shelton MJ, Studenberg S: Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet. 2006;45(2):137-68.</reference_text>
        <pubmed_id>16485915</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fosamprenavir</name>
        <accession>HMDB15416</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fosphenytoin</name>
        <accession>HMDB15417</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF: Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4.  Curr Drug Metab. 2008 May;9(4):310-22.</reference_text>
        <pubmed_id>18473749</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Josamycin</name>
        <accession>HMDB15418</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cefradine</name>
        <accession>HMDB15428</accession>
      </metabolite>
      <reference>
        <reference_text>Yasuda K, Ranade A, Venkataramanan R, Strom S, Chupka J, Ekins S, Schuetz E, Bachmann K: A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos. 2008 Aug;36(8):1689-97. Epub 2008 May 27.</reference_text>
        <pubmed_id>18505790</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tasosartan</name>
        <accession>HMDB15439</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3'-Hydroxyhexobarbital</name>
        <accession>HMDB13940</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Troleandomycin</name>
        <accession>HMDB15448</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinupristin</name>
        <accession>HMDB15455</accession>
      </metabolite>
      <reference>
        <reference_text>Rubinstein E, Prokocimer P, Talbot GH: Safety and tolerability of quinupristin/dalfopristin: administration guidelines.  J Antimicrob Chemother. 1999 Sep;44 Suppl A:37-46.</reference_text>
        <pubmed_id>10511396</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinupristin</name>
        <accession>HMDB15455</accession>
      </metabolite>
      <reference>
        <reference_text>Bearden DT: Clinical pharmacokinetics of quinupristin/dalfopristin.  Clin Pharmacokinet. 2004;43(4):239-52.</reference_text>
        <pubmed_id>15005638</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinupristin</name>
        <accession>HMDB15455</accession>
      </metabolite>
      <reference>
        <reference_text>Delgado G Jr, Neuhauser MM, Bearden DT, Danziger LH: Quinupristin-dalfopristin: an overview.  Pharmacotherapy. 2000 Dec;20(12):1469-85.</reference_text>
        <pubmed_id>11130220</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cortisone acetate</name>
        <accession>HMDB15459</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cortisone acetate</name>
        <accession>HMDB15459</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.</reference_text>
        <pubmed_id>10490933</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paramethasone</name>
        <accession>HMDB15462</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Paramethasone</name>
        <accession>HMDB15462</accession>
      </metabolite>
      <reference>
        <reference_text>Ekins S, Bravi G, Wikel JH, Wrighton SA: Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.</reference_text>
        <pubmed_id>10490933</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Yohimbine</name>
        <accession>HMDB15464</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bezafibrate</name>
        <accession>HMDB15465</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Colchicine</name>
        <accession>HMDB15466</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Digitoxin</name>
        <accession>HMDB15468</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tiotropium</name>
        <accession>HMDB15479</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ciclesonide</name>
        <accession>HMDB15480</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pranlukast</name>
        <accession>HMDB15481</accession>
      </metabolite>
      <reference>
        <reference_text>Nakade S, Yamauchi A, Komaba J, Ohno T, Kitagawa J, Honda N, Hasegawa C, Yoneda K, Kodama Y, Yasuda K, Azuma J, Miyata Y: Effect of clarithromycin on the pharmacokinetics of pranlukast in healthy volunteers. Drug Metab Pharmacokinet. 2008;23(6):428-33.</reference_text>
        <pubmed_id>19122337</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acenocoumarol</name>
        <accession>HMDB15487</accession>
      </metabolite>
      <reference>
        <reference_text>Ufer M: Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44(12):1227-46.</reference_text>
        <pubmed_id>16372822</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acenocoumarol</name>
        <accession>HMDB15487</accession>
      </metabolite>
      <reference>
        <reference_text>Morales-Molina JA, Arrebola MA, Robles PA, Mangana JC: Possible interaction between topical terbinafine and acenocoumarol.  Ann Pharmacother. 2009 Nov;43(11):1911-2. Epub 2009 Oct 20.</reference_text>
        <pubmed_id>19843835</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylaminopyrine</name>
        <accession>HMDB13839</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>N-Desmethylaminopyrine</name>
        <accession>HMDB13839</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Allylestrenol</name>
        <accession>HMDB15500</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3-Hydroxymethylantipyrine</name>
        <accession>HMDB13840</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3-Hydroxymethylantipyrine</name>
        <accession>HMDB13840</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethylmorphine</name>
        <accession>HMDB15509</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Flunitrazepam</name>
        <accession>HMDB15510</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bromazepam</name>
        <accession>HMDB15511</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Clotiazepam</name>
        <accession>HMDB15512</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketazolam</name>
        <accession>HMDB15526</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ketazolam</name>
        <accession>HMDB15526</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Prazepam</name>
        <accession>HMDB15527</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quazepam</name>
        <accession>HMDB15528</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Everolimus</name>
        <accession>HMDB15529</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Solifenacin</name>
        <accession>HMDB15530</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nitrazepam</name>
        <accession>HMDB15534</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lopinavir</name>
        <accession>HMDB15539</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Lopinavir</name>
        <accession>HMDB15539</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Deferasirox</name>
        <accession>HMDB15547</accession>
      </metabolite>
      <reference>
        <reference_text>Skerjanec A, Wang J, Maren K, Rojkjaer L: Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers. J Clin Pharmacol. 2010 Feb;50(2):205-13. Epub 2009 Nov 25.</reference_text>
        <pubmed_id>19940232</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pipotiazine</name>
        <accession>HMDB15558</accession>
      </metabolite>
      <reference>
        <reference_text>Wojcikowski J, Boksa J, Daniel WA: Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver--A comparison with other phenothiazines. Biochem Pharmacol. 2010 Oct 15;80(8):1252-9. Epub 2010 Jul 6.</reference_text>
        <pubmed_id>20615392</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>6-Hydroxymethyletoricoxib</name>
        <accession>HMDB13997</accession>
      </metabolite>
      <reference>
        <reference_text>Takemoto JK, Reynolds JK, Remsberg CM, Vega-Villa KR, Davies NM: Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib.  Clin Pharmacokinet. 2008;47(11):703-20.</reference_text>
        <pubmed_id>18840026</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>6-Hydroxymethyletoricoxib</name>
        <accession>HMDB13997</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>6-Hydroxymethyletoricoxib</name>
        <accession>HMDB13997</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rutin</name>
        <accession>HMDB03249</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dalfopristin</name>
        <accession>HMDB15566</accession>
      </metabolite>
      <reference>
        <reference_text>Rubinstein E, Prokocimer P, Talbot GH: Safety and tolerability of quinupristin/dalfopristin: administration guidelines.  J Antimicrob Chemother. 1999 Sep;44 Suppl A:37-46.</reference_text>
        <pubmed_id>10511396</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dalfopristin</name>
        <accession>HMDB15566</accession>
      </metabolite>
      <reference>
        <reference_text>Lamb HM, Figgitt DP, Faulds D: Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs. 1999 Dec;58(6):1061-97.</reference_text>
        <pubmed_id>10651391</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dalfopristin</name>
        <accession>HMDB15566</accession>
      </metabolite>
      <reference>
        <reference_text>Bearden DT: Clinical pharmacokinetics of quinupristin/dalfopristin.  Clin Pharmacokinet. 2004;43(4):239-52.</reference_text>
        <pubmed_id>15005638</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dalfopristin</name>
        <accession>HMDB15566</accession>
      </metabolite>
      <reference>
        <reference_text>Delgado G Jr, Neuhauser MM, Bearden DT, Danziger LH: Quinupristin-dalfopristin: an overview.  Pharmacotherapy. 2000 Dec;20(12):1469-85.</reference_text>
        <pubmed_id>11130220</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Niacinamide</name>
        <accession>HMDB01406</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Thiotepa</name>
        <accession>HMDB15576</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bifonazole</name>
        <accession>HMDB15583</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>3-O-beta-D-Galactopyranosyl-L-arabinose</name>
        <accession>HMDB38854</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Maraviroc</name>
        <accession>HMDB15584</accession>
      </metabolite>
      <reference>
        <reference_text>Abel S, Back DJ, Vourvahis M: Maraviroc: pharmacokinetics and drug interactions.  Antivir Ther. 2009;14(5):607-18.</reference_text>
        <pubmed_id>19704163</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Maraviroc</name>
        <accession>HMDB15584</accession>
      </metabolite>
      <reference>
        <reference_text>Abel S, Jenkins TM, Whitlock LA, Ridgway CE, Muirhead GJ: Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol. 2008 Apr;65 Suppl 1:38-46.</reference_text>
        <pubmed_id>18333864</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Maraviroc</name>
        <accession>HMDB15584</accession>
      </metabolite>
      <reference>
        <reference_text>Mannu J, Jenardhanan P, Mathur PP: A computational study of CYP3A4 mediated drug interaction profiles for anti-HIV drugs. J Mol Model. 2011 Aug;17(8):1847-54. Epub 2010 Nov 16.</reference_text>
        <pubmed_id>21080015</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ixabepilone</name>
        <accession>HMDB15593</accession>
      </metabolite>
      <reference>
        <reference_text>Goel S, Cohen M, Comezoglu SN, Perrin L, Andre F, Jayabalan D, Iacono L, Comprelli A, Ly VT, Zhang D, Xu C, Humphreys WG, McDaid H, Goldberg G, Horwitz SB, Mani S: The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res. 2008 May 1;14(9):2701-9.</reference_text>
        <pubmed_id>18451235</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nilotinib</name>
        <accession>HMDB15595</accession>
      </metabolite>
      <reference>
        <reference_text>Tanaka C, Yin OQ, Smith T, Sethuraman V, Grouss K, Galitz L, Harrell R, Schran H: Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol. 2011 Jan;51(1):75-83. Epub 2010 Aug 11.</reference_text>
        <pubmed_id>20702754</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nilotinib</name>
        <accession>HMDB15595</accession>
      </metabolite>
      <reference>
        <reference_text>Haouala A, Widmer N, Duchosal MA, Montemurro M, Buclin T, Decosterd LA: Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood. 2011 Feb 24;117(8):e75-87. Epub 2010 Sep 1.</reference_text>
        <pubmed_id>20810928</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nilotinib</name>
        <accession>HMDB15595</accession>
      </metabolite>
      <reference>
        <reference_text>Yin OQ, Gallagher N, Tanaka C, Fisher D, Sethuraman V, Zhou W, Lin TH, Heuman D, Schran H: Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study. Clin Ther. 2009;31 Pt 2:2459-69.</reference_text>
        <pubmed_id>20110053</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nilotinib</name>
        <accession>HMDB15595</accession>
      </metabolite>
      <reference>
        <reference_text>Deremer DL, Ustun C, Natarajan K: Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther. 2008 Nov;30(11):1956-75.</reference_text>
        <pubmed_id>19108785</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Permethrin</name>
        <accession>HMDB15604</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trabectedin</name>
        <accession>HMDB15609</accession>
      </metabolite>
      <reference>
        <reference_text>Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1.</reference_text>
        <pubmed_id>19515014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trabectedin</name>
        <accession>HMDB15609</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rotigotine</name>
        <accession>HMDB15615</accession>
      </metabolite>
      <reference>
        <reference_text>Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists.  Curr Top Med Chem. 2008;8(12):1049-67.</reference_text>
        <pubmed_id>18691132</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Telaprevir</name>
        <accession>HMDB15616</accession>
      </metabolite>
      <reference>
        <reference_text>Kim JJ, Culley CM, Mohammad RA: Telaprevir: an oral protease inhibitor for hepatitis C virus infection.  Am J Health Syst Pharm. 2012 Jan 1;69(1):19-33.</reference_text>
        <pubmed_id>22180548</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sertindole</name>
        <accession>HMDB15618</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mianserin</name>
        <accession>HMDB15620</accession>
      </metabolite>
      <reference>
        <reference_text>Rojdmark S, von Bahr C: [Metabolic interaction between psychopharmaceuticals. Probable cause of exacerbation of hypothyroidism according to a case report]. Lakartidningen. 2002 Jun 20;99(25):2854-6.</reference_text>
        <pubmed_id>12143142</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Mianserin</name>
        <accession>HMDB15620</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rimonabant</name>
        <accession>HMDB15623</accession>
      </metabolite>
      <reference>
        <reference_text>Leite CE, Mocelin CA, Petersen GO, Leal MB, Thiesen FV: Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity. Pharmacol Rep. 2009 Mar-Apr;61(2):217-24.</reference_text>
        <pubmed_id>19443932</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Rimonabant</name>
        <accession>HMDB15623</accession>
      </metabolite>
      <reference>
        <reference_text>Lazary J, Juhasz G, Hunyady L, Bagdy G: Personalized medicine can pave the way for the safe use of CB(1) receptor antagonists. Trends Pharmacol Sci. 2011 May;32(5):270-80. Epub 2011 Apr 16.</reference_text>
        <pubmed_id>21497918</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Udenafil</name>
        <accession>HMDB15628</accession>
      </metabolite>
      <reference>
        <reference_text>Ji HY, Lee HW, Kim HH, Kim DS, Yoo M, Kim WB, Lee HS: Role of human cytochrome P450 3A4 in the metabolism of DA-8159, a new erectogenic. Xenobiotica. 2004 Nov-Dec;34(11-12):973-82.</reference_text>
        <pubmed_id>15801542</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Udenafil</name>
        <accession>HMDB15628</accession>
      </metabolite>
      <reference>
        <reference_text>Ku HY, Ahn HJ, Seo KA, Kim H, Oh M, Bae SK, Shin JG, Shon JH, Liu KH: The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90. Epub 2008 Feb 28.</reference_text>
        <pubmed_id>18308836</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sitaxentan</name>
        <accession>HMDB15629</accession>
      </metabolite>
      <reference>
        <reference_text>Stavros F, Kramer WG, Wilkins MR: The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects. Br J Clin Pharmacol. 2010 Jan;69(1):23-6.</reference_text>
        <pubmed_id>20078609</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Sitaxentan</name>
        <accession>HMDB15629</accession>
      </metabolite>
      <reference>
        <reference_text>Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J: Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest. 2002 Jun;121(6):1860-8.</reference_text>
        <pubmed_id>12065350</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Saxagliptin</name>
        <accession>HMDB15634</accession>
      </metabolite>
      <reference>
        <reference_text>Upreti VV, Boulton DW, Li L, Ching A, Su H, Lacreta FP, Patel CG: Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects. Br J Clin Pharmacol. 2011 Jul;72(1):92-102. doi:       10.1111/j.1365-2125.2011.03937.x.</reference_text>
        <pubmed_id>21651615</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Saxagliptin</name>
        <accession>HMDB15634</accession>
      </metabolite>
      <reference>
        <reference_text>Patel CG, Kornhauser D, Vachharajani N, Komoroski B, Brenner E, Handschuh del Corral M, Li L, Boulton DW: Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects. Diabetes Obes Metab. 2011 Jul;13(7):604-14. doi:       10.1111/j.1463-1326.2011.01381.x.</reference_text>
        <pubmed_id>21332626</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Saxagliptin</name>
        <accession>HMDB15634</accession>
      </metabolite>
      <reference>
        <reference_text>Scheen AJ: Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.  Clin Pharmacokinet. 2010 Sep;49(9):573-88. doi: 10.2165/11532980-000000000-00000.</reference_text>
        <pubmed_id>20690781</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Artemether</name>
        <accession>HMDB15643</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fesoterodine</name>
        <accession>HMDB15648</accession>
      </metabolite>
      <reference>
        <reference_text>Malhotra B, Guan Z, Wood N, Gandelman K: Pharmacokinetic profile of fesoterodine.  Int J Clin Pharmacol Ther. 2008 Nov;46(11):556-63.</reference_text>
        <pubmed_id>19000553</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fesoterodine</name>
        <accession>HMDB15648</accession>
      </metabolite>
      <reference>
        <reference_text>Malhotra B, Dickins M, Alvey C, Jumadilova Z, Li X, Duczynski G, Gandelman K: Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. Br J Clin Pharmacol. 2011 Aug;72(2):263-9. doi: 10.1111/j.1365-2125.2011.04007.x.</reference_text>
        <pubmed_id>21545485</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fesoterodine</name>
        <accession>HMDB15648</accession>
      </metabolite>
      <reference>
        <reference_text>Malhotra B, Sachse R, Wood N: Evaluation of drug-drug interactions with fesoterodine.  Eur J Clin Pharmacol. 2009 Jun;65(6):551-60. Epub 2009 Apr 4.</reference_text>
        <pubmed_id>19347334</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fesoterodine</name>
        <accession>HMDB15648</accession>
      </metabolite>
      <reference>
        <reference_text>Malhotra BK, Wood N, Sachse R: Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. Int J Clin Pharmacol Ther. 2009 Sep;47(9):570-8.</reference_text>
        <pubmed_id>19761716</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methyltestosterone</name>
        <accession>HMDB15655</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Nilvadipine</name>
        <accession>HMDB15657</accession>
      </metabolite>
      <reference>
        <reference_text>Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24.</reference_text>
        <pubmed_id>19934256</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fospropofol</name>
        <accession>HMDB15661</accession>
      </metabolite>
      <reference>
        <reference_text>Lejus C, Fautrel A, Malledant Y, Guillouzo A: Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.</reference_text>
        <pubmed_id>12234619</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fosaprepitant</name>
        <accession>HMDB15662</accession>
      </metabolite>
      <reference>
        <reference_text>Navari RM: Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2008 Nov;8(11):1733-42.</reference_text>
        <pubmed_id>18983233</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Fosaprepitant</name>
        <accession>HMDB15662</accession>
      </metabolite>
      <reference>
        <reference_text>Sanchez RI, Wang RW, Newton DJ, Bakhtiar R, Lu P, Chiu SH, Evans DC, Huskey SE: Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos. 2004 Nov;32(11):1287-92. Epub 2004 Aug 10.</reference_text>
        <pubmed_id>15304427</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tofisopam</name>
        <accession>HMDB15699</accession>
      </metabolite>
      <reference>
        <reference_text>Toth M, Bajnogel J, Egyed A, Drabant S, Tomlo J, Klebovich I: [Effect of tofisopam on CYP3A4 enzyme activity on human recombinant 3A4 supersome]. Acta Pharm Hung. 2005;75(4):195-8.</reference_text>
        <pubmed_id>16711396</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ticagrelor</name>
        <accession>HMDB15702</accession>
      </metabolite>
      <reference>
        <reference_text>Teng R, Oliver S, Hayes MA, Butler K: Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010 Sep;38(9):1514-21. Epub 2010 Jun 15.</reference_text>
        <pubmed_id>20551239</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
